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Introduction
Scientific Motivation
Thanks to their citotoxicity, ionizing radiations are widely used in cancer treatment (ra-
diotherapy). In fact, interacting with biological tissues they can damage cancer cell genetic
material preventing cell proliferation. The purpose of radiotherapy is to release a great
dose of ionizing radiation inside the tumor mass, in order to inactivate its proliferative
capacity and at the same time to minimize the dose to normal tissues surrounding the
tumor, in order to reduce treatment’s side effects. For this reason it is mandatory to find
an optimal balance between the tumor local control and the risk of early and late effects
that could compromise patient’s life quality.
Nowadays photon beams produced by bremmstrahlung processes in Linear Accel-
erator (LINAC) are the kind of radiation most used in radiotherapy and for this reason
photon beams are considered to be the reference radiation for radiotherapy treatment.
The use of modern linear accelerator has become a more and more precise tool, capable
of depositing photon dose into a well-defined volume in such a way that radiotherapy
has become a very important treatment modality for many cancers. This has been pos-
sible thanks to a great improvement in technology, culminated in the state of the art
Intensity Modulated Radiation Therapy (IMRT).
In recent years hadrontherapy, a new modality of radiotherapy that exploits charged
hadrons such as protons and light ions (in particular carbon ions), has begun to spread
out with the purpose of overcoming the limitation of photon therapy, leading to a bet-
ter tumor local control and reducing the treatment’s side effects. The advantages of this
new technique are mainly linked to physical aspects, such as the modality of charged
hadron interaction with matter described by the Bethe-Bloch equation. According to
this equation for charged hadrons, the released dose is described by the Bragg curve,
which shows a peak at the end of particle path. Thus, it is possible to deliver very high
doses inside the tumor volume, sparing normal tissues surrounding it, simply by appro-
priately accelerating the hadrons.
Moreover, charged particles (expecially heavy ions) have a greater biological effective-
ness in damaging irradiated cancer cells when compared to photons. As a matter of fact,
in correspondence of the Bragg peak the density of ionizing events increases leading to
a greater biological effectiveness. These properties suggest that with hadrontherapy it
may be possible to achieve better cancer treatment results for deep-seated and radiore-
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sistant tumors.
In order to obtain better tumor local control and to reduce metastasis risk, nowa-
days combined therapies are under investigation with widely increasing interest for the
treatment of particularly resistant tumors, exploiting chemotherapy agents and radia-
tion used in conjunction. In fact, it is known that some drugs have radio-sensitizing
effects, for example stopping cells in the most radio-sensitive phase of their cycle or
inhibiting the repair mechanisms of DNA (DeoxyriboNucleic Acid), amplifying the ra-
diation anti-proliferative effect. Many studies with different kind of chemical agents
used in combination with photon beams have been performed for different cancers, but
at the moment very few data about the use of chemical agents combined with hadrons
are available.
Thesis overview
The present project is a part of the RDH1/IRPT2 project, sponsored by the Istituto Nazionale
di Fisica Nucleare.
The purpose of the study described in this Thesis is the investigation of the inter-
action of charged hadrons (protons and carbon ions) and a new-generation chemother-
apy agent, named Epothilone B, in different human cancer cells cultured in vitro. Since
photon beams are the reference radiation in radiotherapy, a comparison of the obtained
results with those of similar experiments on the interaction of Epothilone B with photon
beams has been done.
Different biological end-points have been evaluated in irradiated human cancer cells
pre-treated or not with Epothilone B. In particular, clonogenic survival, cell growth and
invasive capacity have been investigated. To compare hadrons effectiveness with respect
to photons, the RBE (Relative Biological Effectiveness) has been calculated for protons
and carbon ions, starting from the experimental obtained results.
In order to evaluate the potential advantages of such a combined therapy, the interac-
tion between radiation and drug has been studied. In particular, it is crucial to under-
stand whether the interaction mechanism between the two cytotoxic agents is additive
or synergic (resulting in a greater effectiveness in respect with the sum of the single ra-
diotherapy and chemotherapy). For this reason, an analysis based on different definition
of additivity between citotoxic agents has been performed.
Experiments with hadron and photon beams have been performed at the Centro Nazionale
di Adroterapia Oncologica (CNAO) in Pavia and at the Istituto Nazionale dei Tumori in
Milano (IRCCS foundation), respectively.
The present thesis consists of three parts, for a total of seven chapters. In the first
part, the main concepts of Radio-chemotherapy will be introduced. The second part is
devoted to the description of the experimental procedure and of the data analysis. In the
third part the obtained results will be presented and discussed.
The first chapter will introduce the main concept of Radiobiology for Radiation Therapy,
focusing on those aspect that are crucial for the presented study. In the following chap-
1Research and Development in Hadrontherapy
2Innovation in Radio and Particle Therapy
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ter the fundamental of radiotherapy will be discussed and the main differences between
conventional radiotherapy and hadron therapy will be presented. In Chapter 3 the ratio-
nale of combining radio- and chemotherapy will be introduced and the main properties
of Epothilone B (the chemotherapy drug used in this study) will be presented. Chapter
4 will be devoted to the description of preliminary measurements necessary to charac-
terize the biological system and the chemotherapy drug. In Chapter 5 the experimental
setup and procedure will be described, while Chapter 6 and 7 will be devoted to the
description of the data analysis and to the discussion of the experimental results, respec-
tively.

CHAPTER 1
Radiobiology for Radiation Therapy
Giving a complete definition of Radiobiology is quite hard, considering that it is a very
multidisciplinary science exploiting physical, chemical and biological aspects. In a very
general way, Radiobiology can be defined as a science investigating the interaction of
ionizing radiations with living organism (cells, tissues, plants, animals and human be-
ings) through excitation and ionization processes. Due to its social implication, Radio-
biology has been spreading out since the last century, in parallel with the discoveries in
the field of Nuclear Physics. The first radiobiological observations rapidly followed the
discovery of X-rays: tumor induction, skin reactions, damages of intestinal epithelium
and so on have been qualitatively described since 1902.
X-rays have been gradually introduced in diagnostic and radiation started to be ap-
plied in cancer therapy, due to their lethal effect. In 1906 Bergonie´ and Tribondeau for-
mulated a law, still substantially valid, according to which radiations result more effec-
tive in highly-proliferating tissues. Moreover, they definitely confirmed the cancerous
action of radiation on normal tissues and they started to discuss the role of fractionated
irradiation in radiotherapy treatments.
In the Thirties, new hypothesis concerning biological radiation effects through ”in-
direct radiation action” begun to spread out, stimulated by the new findings on water
radiochemistry: radiation-water reaction products (radicals, ions, molecular products)
can diffuse in materials irradiated in the aqueous phase and modify molecules. The ris-
ing of these new theories, as well as the progress of biochemistry, gave a big contribution
on Radiobiology development.
Since 1945 it was registered a huge increase in radiobiological literature, justified by
the explosion of nuclear weapons in Japan, by a long series of nuclear tests during the
Fifties and by the diffusion of nuclear power plants. Starting from this years, in vitro and
molecular radiobiology hugely spread out in parallel with in vivo radiobiology studies
on little animals.
Many effects such as the Oxygen Effect or the role of chemical radioprotector begun
to be systematically studied. Research on molecular DNA repair mechanism, chromo-
somes’ damages and comparison between the effectiveness of different types of radia-
tion started in this years.
Nowadays Radiobiology have drastically spread out and is involving more and more
physical, genetical, chemical, immunological and biological aspects. Various biological
end-point are being studied both in vitro and in vivo for many different applications:
1
2improvements in radiation therapy, in nuclear medicine and diagnostic as well as studies
on appropriate shielding for interplanetary mission and so on.
In the field of Radiotherapy, Radiobiology is giving an increasing contribution, iden-
tifying more and more precisely the mechanisms at the basis of the tumor and normal
tissue response to irradiation.
Thanks to in vitro radiobiology studies, it has been possible to quantitatively determine
dose-effect dependencies. In particular, the surviving fraction of irradiated cells has been
studied as a function of dose, and models to describe cell response to irradiation have
been introduced (i.e. the ”linear-quadratic model”). Quantities such as The Oxygen En-
hancement Ratio have been introduced to better quantify cell response to irradiation in
different condition, for example in the case of hypoxic tissues.
Since for many years radiation therapy exploited photon irradiation, photon beams are
considered to be the reference radiation in radiotherapy. Nowadays another kind of ther-
apy, named hadrontherapy, which takes advantage of charged particles energy deposi-
tion in biological tissues is spreading out for cancer treatment. Radiobiology is giving an
important contribution in the development of this kind of therapy, comparing biological
effects of charged particles to that of photons and identifying quantities such as the Rel-
ative Biological Effectiveness.
Moreover, bio-molecular and genetic studies are being performed to better understand
the mechanism that regulate healthy and cancer cells response to irradiation.
The present study is in the field of in vitro radiobiological studies on radiotherapy
(in particular hadrontherapy) combined with chemical agents. As a matter of fact, the
clinical interest in the so-called combined therapies that exploit different citotoxic agents
such as radiation and chemotherapy drug is recently rising, with the aim of obtaining
better and better results in cancer treatment. From this point of view, Radiobiology can
give an important contribution in the study of the response of cancer cells treated with
drugs and irradiated, analyzing different end-points and quantitatively identifying the
interaction mechanism between radiation and chemical agents.
The main goal of this study is to understand whether the interaction between charged
particle beams used in hadrontherapy (proton and carbon ion beams) and the chemother-
apy agent Epothilone B is additive or synergic and to analyze different end-points (i.e.
clonogenic survival, invasive capability and cell growth) after cell exposure to radiation
and Epothilone B.
Other important aspects of this work are the determination of charged particle Relative
Biological Effectiveness and the comparison of results obtained with charged particles
with those obtained with photons, that, as mentioned before, are the reference radiation
in Radiotherapy.
In this Chapter the main physical quantities and principles of in vitro Radiobiology
will be introduced, focusing on the aspects that are more important for the present study,
such as the biological effectiveness of different radiation types and the effects of radia-
tion at cellular level.
In particular the main differences in cell response to photons or charged particle irradi-
ation will be described.
Radiobiology for Radiation Therapy 3
1.1 Absorbed Dose and Linear Energy Transfer
The fundamental physical quantities in Radiobiology are the Adsorbed Dose and the
Linear Energy Transfer.
The Adsorbed Dose was introduced by the International Commission of Radiation
Units and Measurements in 1971 (ICRU, 1971), in order to describe the effects of energy
losses by ionizing radiation in the material.
It is a non-stochastic quantity, defined as the ratio between the mean energy dE de-
posited by ionizing radiation, and the unit of mass, dm:
D =
dE
dm
(1.1)
The energy dE is the difference between all the energy entering the considered volume
and the energy leaving the volume, taking into account any mass-energy conversion
within the volume. Energy deposition occurs in a stochastic way; thus, this definition is
meaningful only if the elementary mass dm is great enough to guarantee a statistically
relevant number of energy releases. In the International System, the unit used to express
the dose is the Gray (Gy): 1Gy = 1Jkg−1.
The adsorbed dose is a crucial quantity in Radiobiology, because it describes in a macro-
scopic way the energy released by ionizing radiation interacting with matter, but it is
not enough to completely describe and predict the biological effects: other parameters
are needed, such as the Linear Energy Transfer, the Relative Biological Effectiveness and the
Oxygen Enhancement Ratio. These parameters will be discussed more in detail in the next
sections.
The biological effectiveness dramatically depends on radiation-matter interaction
modes. For electromagnetic radiation ionizations are uniformly distributed, while for
particles they are localized in proximity of the particle’s track. For this reason it is im-
portant to introduce a quantity that takes into account the energy locally released by ra-
diation: the Linear Energy Transfer (LET). It is defined as the average energy deposited
per unit length of radiation track in the crossed medium:
LET =
dE
dx
(1.2)
In order to quantify the energy locally transferred in the medium along the track, an en-
ergy threshold 4 is introduced: it corresponds to the range of secondary electrons over
which the energy release is no more considered to be local. If 4 is large enough to con-
sider every energy deposition to be local, the Linear Energy Transfer coincides with the
Stopping Power.
High-LET radiations release great energy amount in a short path, causing complex dam-
ages to every structure near the particle track. For this reason, high-LET radiation bio-
logical damages are poorly repaired in a correct way. In figure 1.1 a comparison between
the energy depositions in a typical cellular volume for low and high-LET ionizing ra-
diations is shown. In panel a) it is possible to see that the spatial dose distribution of
X-rays is highly uniform; for this reason low LET radiations are called sparsely ionizing
radiations. In the other panels the spatial dose distribution for carbon ions (high-LET
radiation) at 1 MeV/u, 15 MeV/u, 200 MeV/u is reported. In this case the local dose
shows sharp peaks due to the high-LET along the track, and, as the energy increases,
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a background of low dose. The latter contribution is due to low-LET δ rays. high-LET
radiations are called densely ionizing radiations.
Due to their large Stopping Power, heavy ions, such as carbon ions, are classified as
high-LET radiation, whereas protons and photons are typically considered to be low-
LET radiations.
In table 1.1, different radiations’ LET values in water are reported. Since secondary
Figure 1.1: Simulations of microscopic dose distribution by X-rays (a) and carbon ions at different
energies (b,c,d) (Scholz, 2003).The average macroscopic dose is 2 Gy in all the cases.
particles have different charge and velocity, they have different LET values; for this rea-
son an average LET is calculated and, despite not fully describing energy releases at a
microscopic level, it is used to characterize radiation quality.
Moreover, when dealing with thick targets, it is necessary to consider that the LET
changes with depth due to the beam hardening.
Dose and LET concepts do not permit a precise prediction of the energy deposited in a
microscopic site, for this reason microdosimetry affirmed itself. The two main physical
quantities in microdosimetry are the specific energy and the lineal energy. Microdosimet-
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Low-LET Radiation LET [keV/µm]
γ-rays (60Co) 0.3
X-rays (250 kV) 2
X-rays (3 MV) 0.3
protons (200 MeV) 0.4
High-LET Radiation LET [keV/µm]
Neutrons (14 MeV) 2.3
α-particles (5 MeV) 95
Carbon Ions (10-250 MeV/u) 15-170
Heavier Ions 100-2000
Table 1.1: LET values in water for different types of radiation. LET=10keV/µm separate high-LET
from low LET. Data taken from (Podgorsak, 2010).
ric quantities are required when dealing with volumes small enough that the relative
fluctuations of energy deposition are not negligible. Relative fluctuations are larger for
small volumes and small doses. (Kellerer, 1984)
The specific energy z is the random variable corresponding to the absorbed dose. In
order to define the dose starting from the specific energy, it is useful to consider its dis-
tribution function F (z), whose derivative with respect to z represents the probability
density f(z). The absorbed dose is then equal to the mean specific energy:
D = z¯ =
∫∞
0
zf(z)dz
The lineal energy y is the random variable corresponding to the LET and it is defined
as the ratio between the imparted energy and the mean chord lenght. This quantity is
related to energy increments produced by single energy deposition events.
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1.2 Physical and Chemical effect of ionizing radiation in biological
systems
Ionizing radiation can be divided in two groups: directly and indirectly ionizing radia-
tions.
Directly ionizing radiations deposit energy by Coulomb interaction with molecules, di-
rectly exciting and ionizing them. This kind of interaction is typical of charged particles
and its typical time scale is 10−16 s.
Indirectly ionizing radiations deposit energy through a two-step process: interacting
with biological matter, they produce secondary electrons that can excite and ionize molecules
inside the cell. These processes are typical of photon interaction with matter and they
take longer time.
To describe more in detail the biological effect of radiation, we can identify three main
phases that characterize the interaction of ionizing radiation with biological system.
In the Physical phase, radiation ionizes molecules inside the cell. The typical time scale
of this phase varies between 10−16 s and 10−12 s, depending on the kind of radiation
(directly or indirectly ionizing).
The following phase, in which the ionized molecules chemically react causing free-
radical formation, is called chemical phase. Free-radicals are molecules with unpaired
electrons and have high probability to interact with cellular targets (i.e. DNA), modify-
ing their structure and damaging them. This phase takes from 10−12s to 10−6s.
When a charged particle directly ionizes a biologically important molecule inside the cell
(i.e. DNA), we speak about ”direct action” of radiation. This process can be schemati-
cally summarized:
RH → RH + e− → R0 +H+ + e−
When particles ionize, for instance, water molecules inside the cell, the radiation action
is ”indirect”. Most of the damages induced by low-LET radiation (such as photons) are
due to the indirect action, while for high-LET radiation like carbon ions the contribute
of the indirect action to the damages is quite negligible.
In the case of indirect action the chemical phase is more complex, and can be summa-
rized in different steps:
- after the ionization of a water molecule, the free electron produced can be captured
by another molecule. In this way the molecules H2O+ and H2O− are produced. These
molecules are very unstable and they dissociate in 10−10s producing H0, OH−, H+ and
OH0. Other reactions can occur, producing, in particular, hydrated electrons; this elec-
trons are shielded by a water molecule and their life is longer than that of free electrons.
- All these reactions products can diffuse, recombine or react with complex and biologi-
cally important molecules, altering their structures:
RH +OH0 → R0 +H2O
RH +H0 → R0 +H2
The radical R0 is produced both in the case of direct and indirect action. It can alter
the complex structure it belongs to (for example a chromosome), modifying or inhibiting
its functions. When Oxygen is present, the radical R0 reacts with it, becoming a perox-
ide. The peroxide radical is stable, thus the damage cannot be spontaneously repaired
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by recombination with positive ions: the damage is thus fixed.
The biological phase is made up of all the processes that occur after the damages at the
main biological targets. The fixed damages can be repaired through enzymatic processes,
such as the homologous recombination and the nonhomologous end-joining. The effi-
ciency of this repair pathways dramatically depend on the complexity of the damages. If
the repair is successful, no biological damage occur and the cell can undergo its life-cycle
without any problem; otherwise cell death, genetic or cancer effects can take place.
1.2.1 DNA damages
The most critical macromolecule inside the cell is the DNA, contained in the cell nu-
cleus. There are some evidences that DNA is the most important structure in the cell: for
simple organisms it has been possible to find a quantitative relation between biological
functions and DNA damages. In more complex biological systems it has been observed
that the loss of some biological functions can be directly linked to DNA damages.
The typical DNA structure is a double-stranded helix consisting on two long polymers
made up of monomers called nucleotides, each of them constituted by a phosphoric
acid molecule, a molecule of deoxyribose and an organic nitrogenous base (Adenine,
Thymine, Guanine or Cytosine). The two strands are coupled thanks to the complemen-
tarity between nitrogenous bases and their typical distance is of few nanometers.
Nucleotides are arranged in a highly specific sequence that encodes all the genetic in-
formation necessary for the development and correct functioning of living organisms.
Since the genome is contained in a single copy within the cell, it is crucial to preserve
this sequence, to prevent and eventually repair DNA damages.
DNA lesions can occur due to different agents, such as ionizing radiations. For the
Figure 1.2: Single-Strands Breaks (SSB) and Double-Strand Breaks (DSB) in DNA double-helix.
(http://www.bioquicknews.com/node/2696).
present study two kinds of lesions are particularly relevant: Single and Double Strand
Breaks, schematically described in figure 1.2.
Single-Strand Breaks: Only one of the two DNA strands is damaged. This damage
can be easily repaired by the cell, thanks to the undamaged strand that can be used as a
template to reconstruct the damaged one.
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Double-Strand Breaks: both the strands are damaged. If the lesions are far enough from
each other, they can be repaired as single strand breaks, otherwise more complex repair
mechanisms are needed, with lower efficiency. If the lesion is uncorrectly repaired cell
death or chromosome aberrations (leading to carcinogenesis) can occur. Multiple lesions,
formed in few helical turns of the DNA molecule are considered clustered damage, very
complex lesions, sometimes difficult to be repaired. The DSB distribution is dramatically
affected by the radiation type and LET. In figure 1.3 a comparison between the expected
DSB distributions after different LET irradiation is reported.
After DNA damages occurring, cells can undergo different fates; if lesions are not lethal,
Figure 1.3: Simulated patterns of DSB distribution after different LET irradiation in a cell nucleus
(Tommasino and Durante, 2015).
they can report no consequences after irradiation or they can suffer a division delay; oth-
erwise when lethal lesion occurs cells can die via apoptosis (they die before division or just
afterwards by fragmentation into smaller bodies) or undergo a reproductive failure (cells
die attempting the first or the subsequent divisions, definitively loosing their clonogenic
ability).
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1.2.2 Cell damages: clonogenic death
One of the main biological effects in radiotherapy is the reproductive death of irradiated
cells. This is one of the most common end-point studied in Radiobiology: the clonogenic
survival of a single cell is defined as its ability to give rise to a colony of ”daughter”
cells.
It often happens that after being damaged, a single cell is able to divide two or three
times before definitely loosing its clonogenic capacity without further dividing; for this
reason, conventionally a cell is considered to have survived from a clonogenic point of
view when it produces a colony made up of at least 50 cells.
In order to evaluate clonogenic survival as a function of radiation dose, clonogenic
assays can be performed measuring the plating efficiency, as it will be described in Chap-
ter 5.
Usually, the relation between the surviving fraction of an irradiated population and
the radiation dose is plotted as shown in figure 1.4: the surviving fraction is reported on
a logarithmic scale on the ordinate, while dose is plotted on a linear scale on the abscissa.
The shape of the curve depends not only on the kind of irradiated cells, but also on the
type of radiation. In particular, densely ionizing radiations give rise to a cell survival
curve that exponentially depends to radiation dose. For sparsely ionizing radiations, on
the contrary, the curve shows a ”shoulder”, that typically is related to the DNA repair
capacity. In fact, considering that High-LET radiations cause more complex and diffi-
cultly repairable damages, this shoulder does not appear in high-LET radiation survival
curves. Moreover in very radiosensitive cells, lacking efficient repair mechanisms, the
quadratic term is usually small.
At the moment, the most accredited model used to parametrize the dose-survival
curve of irradiated cells is the Linear Quadratic (LQ) Model. This model conjectures that
the lethal lesions are the double strand breaks that can be caused by a single radiation
hit (linearly depending from dose) and by the interaction of two radiation hits (quadrat-
ically depending from dose). Thus, the frequency f of lethal lesions can be expressed as
a function of dose:
f(D) = αD + βD2 (1.3)
In the hypothesis of a random frequency of lethal lesions, the surviving fraction S(D),
representing the fraction of cells carrying no lethal damages, can be expressed according
to the Poisson distribution, obtaining:
S(D) = e−αD−βD
2
(1.4)
For high-LET radiations, the first kind of damages is more probable, so that the β param-
eter is usually negligible in respect with α. Otherwise, for low-LET radiations, the lethal
damage can be caused by the interaction of sub-lethal lesions due to different radiation
hits. For this reason the parameter β is not negligible anymore and dose-survival curves
show the typical shoulder (dominant especially for low doses) reported in figure 1.4.
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Figure 1.4: Dose-Survival curves for low-LET (blue) and high-LET (red) radiation.
1.3 Relative Biological Effectiveness
Nowadays charged particle therapy (in particular with protons) is a consolidate alter-
native to photon radiotherapy. When dealing with different irradiation modalities, it is
necessary to consider the potentially different biological effectiveness of different treat-
ment planning. As a matter of fact, charged particles are characterized by energy releases
that are substantially different from the photon ones, as mentioned before. The increased
LET values of charged particles at the end of their track in respect with photons, usually
reflects in a grater biological effectiveness in cell killing. By the fact, as mentioned in
the previous sections, high-LET (densely ionizing) radiations typically induce a greater
frequency of unrepairable damages. In order to quantify this greater effectiveness, the
Relative Biological Effectiveness (RBE) is introduced.
RBE is defined as the ratio between photon and charged particles dose resulting in
the same level of a given biological effect (i.e. the same surviving fraction).
In figure 1.5 RBE is reported as a function of LET for different particles in V79 cells. It
is possible to notice that RBE increases with LET, reaching a maximum at LET values
equal to 100 − 150 keV/µm; after this maximum, RBE decreases. This behavior can be
explained considering that DNA damages are more effective when the distance between
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two consecutive energy deposition is of the order of few nanometers (the distance be-
tween the two DNA strands). When the radiation is sparsely ionizing, DNA repair is
more efficient, while when the ionization density is very high, overkilling can occour:
apart of the energy released inside the cel nucleus does not have a role in DNA breaks
and at the same time the number of cells crossed by radiation decreases.
RBE depends not only by radiation LET and particle type, but also on multiple physical
Figure 1.5: RBE as a function of LET for different particles in V79 cells (Sorensen et al., 2011).
and biological factors, such as cell types, beam characteristics, the cycle phase in which
cells are irradiated and so on. Even the biological end points studied differently modu-
late RBE values. Despite RBE is nowadays widely use in clinics to define and compare
treatment planning, it is still an issue that needs further investigation, due to its complex
dependence on all the mentioned factors.
In hadron therapy the dose is prescribed in Gy(RBE), following the prescription of
the International Commission on Radiation Units and Measurements ((ICRU, 2007)): for
example, when using a proton RBE of 1.1, a prescription dose of 2 Gy(RBE) in proton
therapy corresponds to a physical dose of 1.8 Gy.
Very important phenomena that can modulate charged particles RBE are the target and
projectile fragmentation, as well as range uncertainties.
1.4 Cell cycle effects
The cell proliferation cycle is made up of two well-defined periods: the synthesis (S) of
DNA, in which the genome is duplicated in order to guarantee that each of the two
daughter cells preserve all the necessary genetic information, and the cell division, named
mitosis (M). These periods are separated by two gaps: G1 and G2. In the G1 phase the
DNA has not yet been duplicated, while the G2 gap separates the S and the M phases.
After the mitosis, cytodieresis occurs.
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Figure 1.6: Dose-survival curves of V79 cells irradiated in different phases of their cycle (Sinclair
and Morton, 1966). Cells irradiated in the G2-M phase are more radiosensitive.
From the comparison between dose-survival curves of synchronized cells irradiated in
different phases of their cycle reported in figure 1.6, it is possible to notice that their
radiosensitivity is very different in different phases. Generally, cells are most most ra-
diosensitive in the G2-M phases. By the fact, during this phase the genetic material is
in duplication and the chromatin is gathered in the chromosomes so that the probability
of DNA breaks induced by radiation increases. Moreover it is well-known how in this
cycle phase, DNA repair pathways are less effective than in the other phases.
This dependence of radiosensitivity from the cell cycle phase, justify the concomitant
use of radiation and drugs able to modify the cell cycle and eventually stop cells in the
G2-M phase, or able to inhibit DNA repair, as we did in the present study.
1.5 Oxygen Enhancement Ratio
As mentioned in section 1.2, the presence of Oxygen in irradiated tissues can modify
the effect of radiation fixing DNA damages that consequently cannot be spontaneously
repaired by free-ions recombination. In order to quantify this effect, the Oxygen En-
hancement Ratio (OER) has been introduced. It is defined as the ratio between the doses
necessary to produce the same level of a certain biological effect in hypoxic or normoxic
conditions:
OER =
Dhypoxic
Dnormoxic
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In scarcely vascularized tumor tissues, the content of Oxygen is generally low, contribut-
ing to tumor radioresistance.
Looking at the graph reported in figure 1.7, it is possible to notice that dealing with
low-LET radiations (LET < 10keV/µm) the OER vary between 2 and 3, while for high-
LET radiation it is normally lower. As a matter of fact, for low LET radiation biological
effects are mainly due to free radicals and to the fixing of the damage made possible by
the presence of Oxygen. In the case of high-LET radiation, the direct breaking of DNA
molecules prevails.
Figure 1.7: OER against LET. The vertical line conventionally separates the low LET region (LET
< 10keV/µm) from the high-LET region (LET > 10keV/µm) (Podgorsak, 2005).
1.6 Dose fractionation effects
Cell response to irradiation can be modulated also by dose fractionation. In fact, de-
livering the same radiation dose in more than a single fraction could produce less cell
killing because sublethal damage repair and cells repopulation occur between a fraction
and the subsequent. The former is prevalent for late-reacting tissues and the latter for
early-reacting ones (Podgorsak, 2005).
From one hand, dose fractionation results in a better therapeutic ratio; anyway, from
the other hand, in a fractionated treatment it is necessary to reach a grater total dose
than in a single section, in order to achieve a desired level of biological damage to the
tumor. The rationale of fractionation can be schematically explained taking into account
two aspects (Podgorsak, 2005): as mentioned before, dose fractioning spares normal tis-
sues thanks to repair of sub-lethal damages and cells repopulation and fractionation can
increase tumor damage by reoxygenation and redistribution of tumor cells.
It has been noticed that dose fractionation effects are significantly reduced in high-
LET radiation exposure. This fact can be explained considering that this radiations
mainly induce directly lethal lesions, so that sub-lethal lesions interaction became negli-
gible.

CHAPTER 2
Fundamentals of Radiotherapy
The main purpose of Radiotherapy is to obtain an optimal tumor local control, avoiding
as much as possible any kind of possible side-effect.
As the conformity of the irradiation to the tumoral volume increases, the probability of
curing the tumor avoiding side-effects becomes greater. For this reason any irradiation
technique which allows a great radiation dose in tumoral tissues is advantageous; in fact,
it is possible to reduce the dose absorbed by healthy tissues, avoiding several complica-
tions and maintaining high the dose to the tumor, or, viceversa, it would be possible to
increase the dose to the tumor and achieve a better local control with a dose to healthy
tissues comparable to the one delivered in conventional therapies.
The use of hadrons in radiotherapy was first suggested by Wilson in 1946. The main
idea was to exploit the physical selectivity of proton and light ion beams in order to
irradiate tumors closed to organ at risk that otherwise would be irradiated. Moreover,
when compared to protons, light ions, such as carbon ions (12C6+), have the advantage
of a greater ionization density at the end of their range, leading to a greater biological ef-
fectiveness (Amaldi, 1999). This property is valuable in the treatment of radio-resistant
tumors. Nowadays, apart from proton beams that are quite diffused, carbon ions are
the light ions most used in hadron therapy. This is due to the fact that, with increasing
atomic number Z, the biological effectiveness increases, but the projectile fragmentation
became less and less negligible, leading to dosimetrical issues. As a matter of fact, car-
bon ion beams seem to be a good compromise between the high biological effectiveness
and the complications arising from the projectile fragmentation.
In the following sections the main physical differences between conventional radio-
therapy and handrontherapy will be discussed more in detail.
2.1 Conventional radiotherapy
Conventional radiotherapy exploits photon beams produced using electron linear accel-
erators (LINAC). This accelerators produce a continuous photon spectrum by bremsstrahlung
processes, slowing down a monochromatic electron beam in a target made up of an
heavy material, such as Tungsten. As showed in figure 2.1, photon beams are character-
ized by an exponential absorption, after a maximum, reached after very few centimeters,
depending on the photon’s maximum energy. This depth is called ”build-up” and corre-
sponds to the maximum range of secondary electrons produced by the primary photons
interacting with the most superficial layers of the irradiated material. In the ionizing
energy region, photons interact with matter by three different processes, each of them
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Figure 2.1: Depth-dose curves in water for 20MeV electrons, photons from a Cobalt source and
8MV LINAC, neutrons and 200 MeV protons (Amaldi, 1999).
dominant in a given energy range: photoelectric effect, Compton effect and pair produc-
tion.
In figure 2.2 photoelectric effect, Compton effect and pair production cross sections
are reported in function of the primary photon energy. In the typical energy range of
photon-radiotherapy, the Compton effect is the dominant one.
In the Compton scattering, a photon interacts with an electron of the absorbing material
and is deflected at an angle ϑ. It transfers a portion of its energy to the recoil electron.
Since all scattering angles are possible, the energy transferred to the electron ranges from
zero to a great portion of the incident photon energy.
The energy of the scattered photon is given by ((Knoll, 2000)):
hν′ =
hν
1 +
hν
m0c2(1− cosϑ)
(2.1)
The angular distribution of scattered photons is described by the Klein-Nishina formula:
dσ
dΩ
= Zr20
(
1
1 + α(1− cosϑ)
)2(
(1 + cos2ϑ)
2
)(
1 +
α2(1− cosϑ)2
(1 + cos2ϑ) [1 + α(1− cosϑ)]
)
(2.2)
where
dσ
dΩ
is the differential scattering cross section, Z is the atomic namber of the ab-
Fundamentals of Radiotherapy 17
Figure 2.2: Photoelectric process, Compton effect and pair production cross sections as a function
of incident photon energy. (Knoll, 2000).
sorber material, r0 is the classical electron radious and α =
hν
m0c2
is the fine structure
constant.
The angular distribution for different energies is reported in a polar plot in figure 2.3.
It is possible to notice that, for the photon energy range typically used in radiotherapy,
photons are scattered mostly in the forward direction.
In photoelectric process, a photon of energy hν interact with an absorber atom. As
a result of this interaction, the photon completely disappears and a photo-electron is
ejected by the atom with an energyE = hν−Eb, whereEb is the electron binding energy
Knoll (2000).
As a consequence of the electron emission, the interaction gives origin to an ionized ab-
sorber atom, with a vacancy in one of the bound shells. This vacancy is filled capturing a
free electron or rearranging electrons from other shells, producing characteristic X-rays
or Auger electrons.
The pair production process is possible if the photon energy exceeds twice the elec-
tron energy rest-mass (1.02 MeV). In the interaction with the Coulomb field of a nucleus,
the photon disappears and origins an electron-positron pair, the energy exceding 1.02
MeV is converted in the kinetic energy of the electron and the positron. As we can see
from figure 2.2, this process is dominant for high energy value of the incoming photon.
Despite the exponential decay of the absorbed dose with depth shown in figure 2.1,
photon beams can be used even to irradiate deep-seated tumors: this can be done us-
ing multiple beams entry ports. To apply this irradiation techniques it is necessary that
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Figure 2.3: Number of photons (incident from the left, energy indicated in the plot) scattered at
angle ϑ (Knoll, 2000).
the accelerating structure has the capability to rotate around an horizontal axis (Amaldi,
1999). The state of art in photon beam radiotherapy is represented by the conformed In-
tensity Modulated RadioTherapy (IMRT), in which tens of non-complanar photon beams
are exploited and their intensity is varied across the irradiation field thanks to variable
collimators and personalized absorbers, in order to achieve a better and better tumor
local control. Also electron beams produced by LINAC can be used for the treatment of
superficial tumors; in fact, as it can be seen in figure 2.1, their dose-profile is character-
ized by a maximum range (that depends on the initial beam’s energy), followed by a low
tail due to bremsstrahlung photons.
2.2 Hadrontherapy
The word ”hadrontherapy” refers to different oncological radiotherapy techniques that
exploits non-elementary particles made of quarks, such as protons, light nuclei and neu-
trons. Nowadays the use of neutron in cancer treatment is becoming less and less im-
portant, while the use of charged hadrons is spreading out: protons and carbon ions are
the most utilized charged particles in radiotherapy treatments.
As shown in figure 2.1, the depth-dose curve of protons is completely different from
that of photons and neutrons; in fact charged hadrons loose their energy interacting with
matter in a very different way from other particles: they are characterized by little lateral
scattering when penetrating matter and they release the maximum energy at the end of
their track, this permits to release high doses even in deep-seated tumor and to spare or-
gans at risk (OAR) in the proximity to the distal part of the tumor volume. In figure 2.4
a comparison between treatment plannings with conventional X-rays and with protons
is displayed: thanks to their finite range, protons spare the OAR anterior to the vertebral
column.
The enhanced selectivity of charged hadron beams, compared to photon beams, allows
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to obtain the same tumor control probability and a smaller normal tissue complication
probability, or viceversa a better tumor control and the same level of normal tissue com-
plications.
Figure 2.4: Dose calculation in a treatment planning for a patient with medulloblastoma. Right
side: irradiation with posterior 4 MV LINAC photon beam. Left side: irradiation with posterior
proton beam (Suit et al., 2003).
Energy losses for charged hadrons are described by the Bethe-Bloch equation (Bethe,
1930; Bloch, 1933), that will be discussed in the next section.
2.2.1 Bethe-Bloch equation
We consider a charged particle, i.e. a proton or a light nucleus, with charge ze and veloc-
ity v passing through a material with atomic number Z and we neglect the interaction
between the moving particle and the nuclei of this material. Thus the dominant mecha-
nism for energy loss is the excitation or ionization of the crossed material. We consider
the interaction of a fast particle with an electron initially at rest at a distance b (called
impact parameter) from the track particle. The essential physics of the energy loss process
can be firstly described using a classical approach (by way of example, see Cottingham
and Greenwood (2001)).
The equation of motion for the fast particle is
dp
dt
= zeE,
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where p and E are the fast particle momentum and the electric field of the rest electron,
respectively. The magnetic field due to the rest electron is considered to be negligible.
The particle acquires a momentum
∆p =
∫
ze · Edt
Its longitudinal component ∆p‖ cancels for symmetry, while the transverse component
∆p⊥ (which is the same both in the laboratory and in the particle frame) is given by
∆p⊥ = pT =
∫
ze · E⊥dt = ze
v
∫
E⊥dx
if we approximate the particle motion by x = vt. This integral can be evaluated applying
the Gauss theorem to a cylindrical surface with radius b and infinite length, around the
particle track.
pT = −
(
ze2
4pi0
)
2
bv
(2.3)
Since momentum is conserved, the rest electron acquires a momentum −pT and, in a
non-relativistic approximation, it gains the energy ∆E, lost by the fast particle.
∆E = − p
2
T
2me
= −2
(
ze2
4pi0
)2
1
b2v2me
(2.4)
where me is the electron rest mass. When the fast particle moves throught a distance
dx in the material it passes a number of electron with impact parameter between b and
b+db given by
Z
ρ
A
(2pibdbdx)
where Z, ρ and A are respectively the atominc number, the mass density and the mass
number of the material.
Thus, the energy lost interacting with these electrons is given by
d2E = −4pi
(
ze2
4pi0
)2
Z
ρ
A
db
bmev2
dx.
Integrating this expression over all the impact parameter between bmin and bmax we
obtain the stopping power:
−dE
dx
= 4pi
(
ze2
4pi0
)2
ρZ
Ame
1
v2
log
(
bmax
bmin
)
(2.5)
bmax and bmin can be estimated with the following consideration (Cottingham and Green-
wood, 2001):
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• due to the Heisemberg indetermination principle, the minimum size of a wave
packet is
~
p
=
~
γmv
. The dimensions of a wave-packet must be less than the im-
pact parameter b in order to apply the classical approach with good approximation.
In the centre of momentum frame, the uncertainty in the position of the two parti-
cles is the same, thus, considering that the fast particle is much more massive than
the electron, in the centre of momentum frame it can be considered to be at rest
while the electron moves with velocity near to v and momentum p ≈ γmev. As a
consequence,
bmin ≈ ~
γmev
.
• at large impact parameter, the energy transfer is small so that it is necessary to take
into account the fact that electrons are bound in atoms and that there is a minimum
ionization energy I. For the indetermination principle, the energy E of a particle can
be known with an uncertainty ∆E =
~
τc
, where τc ≈ b
γv
is the collision time. For
this reason
bmax ≈ ~γv
I
.
The equation 2.5 can be so re-written
−dE
dx
= 4pi
(
e2
4pi0c
)2(
z
β
)2
ρ
Z
meA
log
(
γmec
2β2
I
)
(2.6)
Equation 2.6 is known as Bohr formula and describes the energy loss of a charged par-
ticle heavier than an electron moving through matter.
A calculation of the ionizing energy losses that takes into account relativistic and
density effects has been performed by Bethe and Bloch, leading to the following equation
for the stopping power:
−dE
dx
= 4pi
(
e2
4pi0
)2(
z
cβ
)2
ρ
Z
meA
(
log
(
γmec
2β2
I
)
− β2 − δ(βγ)
2
)
(2.7)
The term δ(βγ) takes into account density effect that inhibits the logaritmical growth on
energy losses at large γ: atoms’ polarization shields the electric field from electrons that
are far from the particle tracks. Thus, collision with this electrons have a lower contribu-
tion to energy loss.
In figure 2.5, it is shown the energy loss (Bethe-Bloch equation 2.7) as a function of
βγ for different materials.
It is possible to distinguish three main region:
• a first region, at low β values, where the energy loss is proportional to 1
β2
: thus, as
the particle slow down the energy loss increases.
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Figure 2.5: Ionizing energy loss as a function of βγ for Hidrogen, Helium, Carbon, Aluminum,
Iron, Tin and Lead
(http://mxp.physics.umn.edu).
• A minimum, whose position is very weakly dependent on the material in which
the particles move. Particles with βγ values proximum to the minimum are called
MIP (Minimum Ionizing Particles) and the energy loss is about 1÷ 2MeV gr−1cm2
• a relativistic rise: the energy loss grows logarithmichally. As previously mentioned,
this rise is limited by the density effect in such a way that at large βγ the energy
loss became constant.
When entering the human body, charged particles used in hadrontherapy are char-
acterised by βγ values in the first region, so that for this particles the energy loss is pro-
portional to the square of their charge and to the inverse of the square of their velocity:
−dE
dx
∝
(
ze
β2
)2
(2.8)
2.2.2 Bragg curve and its applications in hadrontherapy
In figure 2.6 it is reported the Bragg curve, that represents the number of ionization of
charged particles with low β values as a function of the penetration depth for a single
particle an for a parallel beam.
As we know from equation 2.7, for this particles the main contribution to energy
losses is given by z2β−2 and depends on the medium in which particles travel: when
the particles slow down they loose more energy and ionize more. In fact, as we can
see in figure 2.6, there is a sharp peak at the end of the particle track, named Bragg
peak. After reaching this maximum the number of ionization dramatically decrease. This
inverse region is due to electronic capture processes that occure at very low velocity of the
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Figure 2.6: Bragg curve for charged particles heavier than electrons (the solid line represents the
Bragg curve of a single particle, the dashed one represents the Bragg curve of a parallel beam)
(Knoll, 2000).
incident particle and that neutralize it.
For a given particle beam, the depth of the Bragg peak depends on the particle initial
energy and its width on the beam’s energy spread.
When compared to protons, carbon ions are chatacterized by a more sharp Bragg peak,
this is because they are heavier so that they have less straggling. Moreover, due to their
higher atomic number Z, as we can see from equation 2.7, at the end of their track (in the
Bragg peak region) they are more ionizing than protons: this implies a greater biological
effectiveness of carbon ions in damaging the irradiated cells.
In table 2.1 the the widths (in terms of FWHM) and the depths of protons and carbon ions
Bragg peaks in water are reported corresponding to the minimum and the maximum
energies achievable for this particles with the CNAO syncrotron (Mirandola et al., 2015).
Particle Energy Bragg peak width [mm] Bragg peak depth[mm]
p 62.73 MeV 2.8 30
C-12 115.23 MeV/u 0.9 30
p 228.57 MeV 26.1 320
C-12 398.84 MeV/u 9.3 270
Table 2.1: Widths and depths of the Bragg peaks in water for both available particles species for
the minimum and the maximum achievable energies at CNAO (Mirandola et al., 2015).
Hadrontherapy exploit this property of charged particles by selecting particles’ initial
energy in order to irradiate the tumor in a very conformed way, giving a very low dose
at the entrance of the body and to the tissues surrounding the tumor. In order to irradiate
uniformly the whole longitudinal depth of the tumor, the beam energy is varied during
the irradiation in a controlled way, so that it is possible to superimpose many narrow
Bragg peaks and to obtain a Spread Out Bragg Peak (SOBP) as the envelope of all this
peaks (figure 2.7).
The beam energy can be varied in two ways (Amaldi, 1999)
• passive modulation: a tissue-equivalent absorbing material of variable thickness is
interposed in the beam path. This is the most diffused kind of beam modulation in
hadrontherapy.
• active modulation: the beam energy is changed actively during the irradiation. This
modulation is easily feasible in synchrotrons, but it is more difficult with other ac-
celerators such as cyclotrons. At the Centro Nazionale di Adroterapia Oncologica
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(CNAO,Pavia), where the presented study has been performed, they use this kind
of beam modulation to obtain the SOBP.
Figure 2.7: proton Spread Out Bragg Peak (SOBP), obtained as the envelope of many Bragg peaks.
The delivered dose has to be conformed to the tumor shape and size even in the
transverse direction. In the past, this was done with passive spreading systems, through
which hadrons were diffused by a scatterer and their energy was adapted to the tumors
using appropriate absorbers: the transverse form of the irradiation field was defined by
collimators.
More recently rotating gantries and a new active spreading systems have been introduced.
With active systems the target volume is suddivided in thousands of voxels , each of
them being irradiated at successive steps, by sending the proton beam with a section of
very few millimiters in the opportune direction. (Amaldi, 1999).
2.2.3 Residual range
The range of a fast particle is defined as the mean distance it travels before stopping.
In figure 2.8 it is shown the ratio between the intensity of a particle beam and its initial
intensity as a function of the penetration depth: from this graph, it is possible to identify
the mean range (Rm), defined as the depth in the absorbed material necessary to stop
half of the particles. In this picture it is also shown the extrapolated range (Re).
For a particle of initial kinetic energy E0 it can be evaluated from 2.7:
R(E0) =
∫ 0
E0
(
dE
dx
)−1
dE
The integral can be performed numerically for different particles and different mate-
rials.
Statistical fluctuations on
dE
dx
give rise to range statistical fluctuations (straggling).
Range uncertainties introduce practical limitation in clinical treatments. In fact the actual
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Figure 2.8: Mean range and extrapolated range.
Bragg peak position is known with an uncertainty that can be of the order of 3% (Moyers
et al., 2001) of the estimated range. This can implicate risks of serious side effects for
tissues near to the distal end of the Bragg Peak, where the dose gradient is very sharp: in
particular this risk is very serious when an organ which sparing is mandatory is located
at the end of the SOBP.
In order to minimize the risks related to physical range uncertainties, safety margins are
defined in the treatment planning and single fields in the direction of organs at risk are
avoided using multiple fields. From the other hand, multiple fields increase the fraction
of normal tissues being irradiated.
Even biological uncertainties have to be take into account, because they can give rise
to ”biological range extension” (Carabe et al., 2012). As a matter of fact, at the distal
end of the Bragg Peak, dose drastically decreases and in parallel the LET increases; as
a consequence, RBE significantly increases and a greater biological dose is given to the
healthy tissues beyond the tumor. This fact results in greater uncertainties.

CHAPTER 3
Combined treatments: radio-chemotherapy
In the recent years, combined treatments are widely spreading-out in oncological field
and combined therapies that exploit radiation and chemotherapy drugs are being inves-
tigated.
The idea of combining radio- and chemotherapy dates back to the early Seventies. In
1979 Steel and Peckham (1979), focusing on in vitro cytotoxicity, proposed an approach
based on the concept of ”additivity envelope” in order to find a mathematical way to de-
termine whether cell killing in combined treatments is greater than additive, enhancing
the effectiveness of the single chemo- and radiotherapy treatments.
More recently, Bentzen et al. (2007) adapted Steel and Peckham framework, proposing
diverse mechanisms in which the combination of radiation and drug can act. These
mechanisms will be described in the next section.
Luttjeboer et al. (2010) proposed a strategy for the analysis of in vitro radiation-drug in-
teraction. In the present study, we applied this method to determine if the interaction
between charged hadrons or photons and the chemotherapy drug Epothilone B is sim-
ply additive or synergic. The Luttjeboer’s method and its application in our study will
be described in Chapter 5.
3.1 Framework for radiation-drug combination
In this section the Bentzen et al. (2007) framework for radiation-drug combination is
summarized. According to this framework, five mechanisms are proposed to motivate
the combination of radio- and chemotherapy: cytotoxic enhancement, spatial cooperation,
biological cooperation, temporal modulation and normal tissue protection, schematically de-
scribed in figure 3.1.
3.1.1 Cytotoxic enhancement
This mechanism of interaction between radiation and drug is the rationale of the study
presented in this thesis: exploiting drugs able to modify the response of cancer cells to ir-
radiation, for example inhibiting DNA repair, can lead to an enhancement in cell killing,
resulting in better tumor local control.
It is important to underline that in order to exploit this mechanism, the drug must be
administered during or just before irradiation. For this reason, radio- and chemotherapy
should be administrated concomitantly. The main goal of this kind of radiation-drug
combination is a better locoregional control of the disease.
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Figure 3.1: Diagram describing the five different mechanism in which radiation and drug can act
in combined cancer treatments: spatial cooperation, cytotoxic enhancement, normal tissue protec-
tion, temporal modulation and biological cooperation.(Bentzen et al., 2007).
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3.1.2 Spatial cooperation
Since radiotherapy is a locoregional treatment, there is a strong rationale for combining
it with agents that act systemically, such as chemotherapy drugs.
In this case, radiation and drug act independently and an interaction at cellular level
between these two agents is not required. For this reason, in cancer treatments exploit-
ing spatial cooperation, chemotherapy and radiotherapy are usually administrated in
sequence, in order to obtain tumor control both locally and in distant sites.
3.1.3 Protection of normal tissue
The use of drugs that can modulate the response of normal tissue to irradiation, making
them more radioresistant, could permit to enhance the radiation dose given to the tumor,
or to avoid treatment side effects.
Several drugs, such as free-radical scavengers, have been proposed as radioprotectors
for normal tissues. Depending on their action, these drugs can be administrated during,
before or after the radiotherapy treatment.
3.1.4 Temporal modulation
As mentioned in Chapter 1, the rationale in fractionated radiotherapy is given by DNA
repair mechanisms, reoxygenation, redistribution from more to less resistant phases of
cell-cycle and reoxygenation of irradiated tissues. Thus, it is possible to combine irra-
diation with the use of drugs that act on one or more of these mechanisms. Since these
mechanisms act at different time in normal and tumoral tissues, when combining radi-
ation and drug it is possible to optimize tumor control, changing the dose-distribution
over time, varying the time interval between each fraction, the dose per fraction and the
total duration of the radiotherapy treatment.
Even in this case, the main clinical end-point is the locoregional control of the disease.
3.1.5 Biological cooperation
In biological cooperation, radiation and drug target different cells populations. For
example, it is possible to complement radiation effects, administrating drugs that act
specifically on hypoxic tumor cells.
Even in this case the main goal is to obtain a better locoregional control of the tumor and
radio- chemotherapy should be administrated sequentially or concomitantly.
3.2 Combined treatment: radiation and Epothilone B
In concurrent chemoradiotherapy treatments, particular attention is given to Microtubule
Stabilizing Agents (MSAs), that are drugs interfering with the mitotic spindle, such as
the Taxanes. These drugs are able to promote the stabilization of the mitotic spindle,
leading to an accumulation of cells in the G2/M phase of the cell cycle, known to be the
most radiosensitive one, as described in Chapter 1. As a consequence of this arrest in cell
cycle progression, cell proliferation inhibition and cell death via apoptosis and necrosis
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can occur. Some Taxanes, such as Placitaxel, are used not only in chemotherapy treat-
ments, but also as radiosensitizers in combination with radiation. Anyway, the clinical
use of Taxanes is limited for example by multidrug resistance.
In recent years, a great deal of attention has been focused on a new class of MSAs: the
Epothilones. Epothilones act similarly to Taxanes, but they are effective at lower concen-
trations (sub-nanomolar) and they are more water soluble, thus avoiding the use of toxic
excipients and inducing fewer side effects (Altmann et al., 2000).
In the present study, we have evaluated the combination of radiation and Epothilone B
(EPO906, Patupilone), a metabolite of bacterial origin that has been studied both in vitro
and in vivo even in combination with photon beams (by way of example see Kim et al.
(2003); Hofstetter et al. (2005); Baumgart et al. (2012a); Roher Bley et al. (2009)). It has
been used in clinical trials as a chemotherapy drug even for the treatment of glioblas-
tomas (Oehler et al., 2012), and it has also been combined with photon radiotherapy for
the treatment of brain malignancies (Fogh et al., 2010), with encouraging results.
In the next paragraphs, some of the Epothilone B effects reported in literature will be
introduced, with particular emphasis on those effects motivating its use in combination
with radiation.
3.2.1 Epothilone B effects on cell cycle distribution
Epothilone B target tubulin, a globular protein present in cell cytoplasm that is the funda-
mental unit of cytoskeleton’s microtubules. In particular, acting on β-tubulin, Epothilone
B is able to interfere with the mitotic spindle formation, causing cell-cycle arrest in the
G2/M phase, altering the normal cell cycle distribution.
Baumgart et al. (2012b) analyzed the effect of Epothilone B at different concentrations on
cell cycle progression of FaDu and A549 cells using flow cytometry. They treated cells
for 24 hours with Epothilone B at concentrations from 0.1 nM to 10 nM, which is known
to be the maximum concentration tolerate in patient’s plasma. In figure 3.2 the results of
this analysis are shown. It is possible to notice a concentration-dependent accumulation
in the G2/M phase, while the G0/G1 peak gradually reduces. This accumulation in the
most radiosensitive phase of cell cycle is one of the rationale for using Epothilone B in
conjunction with radiation.
Moreover a sub-G1 peak and an hyperdiploid population became more evident when
Epothilone B concentration increase. This aspect will be investigated more in detail in
the next paragraph. According to the study of Baumgart et al. (2012b), treatment at con-
centration lower than 0.25 nM resulted in minor difference in cell cycle. Despite this fact,
radiosensitizing effects induced by Epothilone B in cells irradiate with photon beams
have been reported in literature (Baumgart et al., 2012a; Roher Bley et al., 2013, 2009;
Hofstetter et al., 2005)even at lower concentrations. This aspect will be discussed more
in details in the next Chapter.
3.2.2 Epothilone B-induced cell death mechanism and other effects
As reported by Baumgart et al. (2015) and by Kim et al. (2003), the cytotoxic activity of
Epothilone B induces cell death via apoptosis. The hypodiploid population in the sub-
G1 peak can be seen as an hallmark of apoptosis.
Apoptosis consists in a ”programmed” cell death. Some of the morphological changing
typical of apoptosis are, for instance, nuclear fragmentation, cell shrinkage and chro-
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Figure 3.2: Histograms of cell cycle distribution of FaDu cells after an incubation of 24 hours with
different Epothilone B concentrations. (Baumgart et al., 2012b).
matin condensation. It is a cell-death mechanism highly regulated through enzymatic
processes that occur for example when cell’s DNA is irreparably damaged.
Baumgart et al. (2015) observed the production of hyperdiploid cells after the G2/M
cell cycle block and the presence of multinucleated cells. These events can be interpreted
as indication of mitotic catastrophe. Mitotic catastrophe consist in a sequence of events
caused by an inappropriate cell’s entry in mitosis, it is unrelated to apoptosis, and of-
ten observed in cells missing correctly functioning apoptosis pathways. Moreover this
kind of cell death is typically observed after the treatment with chemicals targeting the
mitotic-spindle formation, such as Epothilone B, or after irradiation.
Epothilone B has also been demonstrated to be able to cross the blood-brain barrier
and to retain in brain tissue in rats, mice and dogs (O’Reilly et al., 2008); this property
makes it a very promising chemotherapy agent for the treatment of brain malignancies.
It has even shown antivascular and antiangiogenic effects (Stalder et al., 2005; Fer-
retti et al., 2011; Bocci et al., 2002) and the ability to effectively inhibit cells’ migration at
non-cytotoxic concentration (Pagano et al., 2012; Furmanova-Hollenstein et al., 2013).
3.2.3 Epothilone B effects on DNA-repair capacity
Through γH2AX foci assays, Baumgart et al. (2012a) found a tendency that Epothilone
B increases the number of double strand breaks after photon irradiation, even at low
concentration (1 nM), suggesting a reduction in DNA damage capacity. In fact, when a
double strand break occurs, the H2AX histone is phosphorilated (γH2AX) as an incipit
of DNA repair pathway. When this repair is inhibited, the number of γH2AX remains
high, as shown in figure 3.3. Thanks to this repair’s inhibition, radiation effectiveness
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Figure 3.3: Mean number of γH2AX foci per cell (after 1h and 24h of repair time) with and without
Epothilone B (A549 cells) (Baumgart et al., 2012a). The presence of this histone can be related to
the presence of Double Strand Breaks.
in damaging DNA can be increased using Epothilone B concomitantly to irradiation, ex-
ploiting the cytotoxic enhancement.
Thanks to the properties described in the previous sections, Epothilone B is suitable
not only to be used as a chemotherapy drug, but also in combination with radiation,
enhancing its effects.
CHAPTER 4
Preliminary measurements: cell lines and Epothilone B
characterization
In this chapter the characterization of the biological systems studied will be introduced.
In particular the main properties of the cell-lines investigated will be presented. More-
over the preliminary measurements performed to characterize Epothilone B will be de-
scribed.
4.1 Biological system
In experiments devoted to the study of radiation effect at cell level, the main advantage
of in vitro biological systems, with respect to in vivo experiments, is the fact that they
ensure a better reproducibility and avoids many issues related to more complex organ-
isms.
In order to study the effects of the combination irradiation - Epothilone B, three different
estabilished cell lines have been used: A549, U251MG and DAOY.
Established cells derives from primary cell cultures. They are not part of the organized
tissues they belong to, but they can maintain their functionality and can indefinitely re-
produce, under suitable culture conditions.
We have chosen these three cell lines because they derives from cancers that can poten-
tially benefit of a chemo-radiotherapy treatment for different reasons.
A549 . This cell line is derived from human lung adenocarcinoma, a kind of non-small
cell lung cancer (NSCLC) that affects the epithelial cell of the bronchial tube and
it is a very common lung neoplasia in non-smokers. It can benefit of combined
chemo-radiotherapy with hadrons because it is quite resistant to conventional ra-
diotherapy and because lungs are very close to organ-at-risk such as the spinal
cord and the esophagus.
U251MG . This cell line is derived from human glioblastoma multiforme (GBM). GBM is
the most frequent primary tumor of the central nervous system. It is particu-
larly aggressive, highly angiogenic and typically it is associated with a very poor
prognosis. One of the main biological features of GBM is the local invasion of
the surrounding brain tissue. Such an invasive behaviour is the main obstacle to
an effective treatment of this tumor (Pagano et al., 2012). Currently, the standard
treatment for glioblastoma combines chemotherapy, radiotherapy and surgical re-
section. Typically after surgical resection, radiotherapy is combined to the use of
TMZ, a DNA-binding agent (Stupp et al., 2009; Mirmanoff et al., 2006). Thus, it can
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be interesting to study the effect of irradiation combined to another chemotherapy
agent such as Epothilone B.
DAOY . This cell line is derived from human pediatric medulloblastoma. It is a tumor of
the posterior cerebral fossa and it is the most common brain tumor in children. This
cell line is a very radiosensitive one, in fact it is derived from a pediatric patient
tissue. Despite being very radiosensitive, this kind of tumor can benefit from a
combined treatment with hadrons (especially protons) due to patient’s youth and
their significantly long life expectation. In fact, a very conformed therapy such
as protontherapy might reduce the probability of secondary cancers induced by
irradiation. Due to the great radiosensitivity of this kind of tumor, an irradiation
with high-LET radiation seems not necessary and, since carbon ion irradiation late
effects are still debated, at the moment proton beams are considered very suitable
for the treatment of pediatric tumors. For this reason, in this thesis, only photon
and proton irradiation have been studied for DAOY cells.
All cell lines were supplied by the ICLC (Interlab Cell Line Collection, Genova, Italy),
and they were stored at −191oC in liquid nitrogen, in a solution containing 40% of
medium, 50% of fetal bovine serum and 10% of dimethyl sulfoxide (DMSO), a cry-
oprotective agent. After thawing, cells were maintained at 37oC in humidified atmo-
sphere containing 5% CO
2
in air as exponentially growing cultures in opportune medi-
ums. A549 cells were cultured in Dulbecco Modified Eagles Medium (DMEM, Sigma-
Aldrich), while U251MG and DAOY were cultured in Eagles Minimum Essential Medium
(EMEM), both supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich) and
Gentamicin (50 µg/ml) (Sigma-Aldrich).
4.2 Cell lines characterization
All the cell lines have been preliminary tested in term of plating efficiency and doubling
time.
4.2.1 Plating efficiency
The plating efficiency (PE) have been measured as the ratio between the number n0 of
cells seeded into a flask T25 and the number of colony-forming cells (giving rise to a
colony made up of at least fifty cells), n.
PE =
n
n0
.
In our experimental conditions, the measured PE for each cell line is reported in table
4.1.
Cell growth
In order to evaluate cell growth parameters, cells were seeded in flasks T25, let grow for
five days and counted at different time. The ratios
n(t)
n0
have been measured as a func-
tion of time, in order to obtain growth curves.
Preliminary measurements: cell lines and Epothilone B characterization 35
cell line PE
A549 80%
U251MG 85%
DAOY 60%
Table 4.1: Plating Efficiency (PE) values for A549, U251MG and DAOY cells.
In figure 4.1 the ratio
n(t)
n0
of A549 cells is reported as a function of time, as an exam-
Figure 4.1:
n(t)
n0
of A549 cells as a function of time.
ple. After a period called lag time that represents the time required for cells to progress
through the cycle, cell growth is exponential. After the exponential growth, the cell cul-
ture become confluent.
Data in the exponential region have been interpolated according to equation:
n(t)
n0
= 2
t
td (4.1)
where td is the doubling time. Fit have been performed with the software OriginLab,
based on χ2 minimization. Details on the fit procedure are reported in Appendix A.
The td values are reported in table 4.2 for each cell line.
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cell line td [hours]
A549 21.2 ± 0.2
U251MG 24 ± 1
DAOY 24 ± 1
Table 4.2: Doubling time (td) values for A549, U251MG and DAOY cells.
The measure of the doubling time was necessary to determine the duration of the
treatment with Epothilone B, in order to guarantee that cells pass through all the phases
of their cycle. For this reason, a treatment time of 24 hours has been chosen.
4.3 Epothilone B characterization
Epothilone B (Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) to generate
a 10µM stock solution. The stock solution was then diluted in medium at opportune
concentrations. The final DMSO concentration were less then 0.1%, this DMSO concen-
tration is known to have no effect on cell survival.
Before starting with the study of the effects of irradiation combined with Epothilone
B, the drug has been tested in term of clonogenic survival, effects on cell invasive capac-
ity and cell cycle, as described in the following paragraphs.
4.3.1 Clonogenic survival
Clonogenic survival vs Epothilone B concentration
Clonogenic survival has been measured by colony forming assay as a function of Epothilone
B concentration. The experimental procedure of colony forming assay will be described
in detail in the next chapter.
Cells (in the phase of exponential growth) have been treated for 24 hours with Epothilone
B at different concentrations. In figure 4.2 the fraction of surviving cells is reported as
a function of Epothilone B concentration for A549, U251MG and DAOY cells. Due to
the different sensitivity of the three cell lines, different concentrations range have been
chosen: 0-0.6 nM for U251MG cells, 0-0.2 nM for A549 cells, 0-0.08 nM for DAOY cells,
which resulted to be the more sensitive to Epothilone B. As shown in figure 4.2, the last
concentration used for each cell line leads to a surviving fraction of about 0.015. It is
possible to see that no effect on cell survival occurred at concentrations lower than 0.05
nM for A549 0.075 nM for U251MG and 0.02 nM for DAOY cells, suggesting the pres-
ence of a threshold concentration (whose value depends on the cell line) under which
the drug has basically no effect on cell proliferative capacity. For concentrations greater
than the threshold value, cells clonogenic survival decreases. This behavior is typical of
cells treated with chemical cytotoxic agents.
This preliminary test was necessary to choose the drug concentration to be used in
conjunction with radiation. A concentration corresponding to a survival level of about
40% has been chosen for each cell line. In table 4.3 the chosen Epothilone B concentration
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are reported.
cell line Epothilone B concentration [nM]
A549 0.075
U251MG 0.125
DAOY 0.035
Table 4.3: Epothilone B concentrations chosen for the combination Epothilone B - irradiation for
each cell line. This concentrations correspond to about the 40% of cell clonogenic survival.
Figure 4.2: Surviving fraction as a function of Epothilone B concentration for U251MG cells (blue),
A549 cells (green), DAOY cells (pink)
Clonogenic survival vs Epothilone B treatment time
Clonogenic survival was measured for cells treated with Epothilone B at the concentra-
tion chosen to be used in combination with radiation for different treatment time (18, 24
and 33 hours).
Collected data highlight that there are no significant cell survival variations in the treat-
ment time interval 18-33 hours.
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4.3.2 Epothilone B effects on invasive capacity
As mentioned in Chapter 3, Epothilone B is known to inhibits cells invasive capacity. We
tested this property in A549 and U251MG cells (that are very invasive) at the concen-
tration chosen for the evaluation of the effects of the combined treatment (0.075 nM for
A549 cells and 0.125 for U251MG cells).
This analysis was performed through invasion assays. The complete procedure for in-
vasion assay will be described in the next Chapter.
The invasive capacity was measured as the ratio between invading cells and the total
number of cells initially seeded (see Chapter 4 for details). Obtained values were then
normalized to the control ones.
In figure 4.3 the invasion rate of A549 and U251MG cells relative to the control sample
(cells not treated with Epothilone B) is displayed. Epothilone B at these concentrations
resulted to inhibit the invasive capacity, reducing the basal invasion rate of A549 to 55%
and of U251MG to 68%.
Figure 4.3: Relative invasion rate for A549 and U251MG cells treated with Epothilone B (0.075 nM
and 0.125 nM, respectively) or not (control sample)
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4.3.3 Epothilone B effects on cell cycle
The effects of Epothilone B on cell cycle were investigated on A549 and U251MG cells at
different concentrations.
The analysis of cell cycle was performed through flow-cytometry in collaboration with
the ”DOSMM - Servizio di Citometria e Cell Sorting” at the Fondazione IRCCS Istituto
Nazionale dei Tumori (Milano).
In flow-cytometry for cell cycle analysis, cells are stained with fluorescent probes able to
intercalate in DNA double-helix. Fluorescence measurements permit to distinguish the
different phases of the cell-cycle. In fact, in the G2 phase, DNA is duplicated in respect
with the G1 phase, so that a double fluorescence intensity is detected. In the S phase
intermediate fluorescence intensity values are found. Moreover, when apoptosis occurs,
DNA is fragmented so that a sub-G1 peak can be identified. A detailed description of
flow-cytometer is given in Appendix B.
For our measurements, we used the Propidium Iodide as fluorescent probe; its exci-
tation length is in the green region and its emission spectrum is in the red region and
has a peak correspondent to 610 nm. This fluorochrome is non fluorescent when free in
solution, while its fluorescence intensifies when it is intercalated in DNA molecules.
In order to fix samples for cytofluorimetric analysis, we followed this procedure: af-
ter treatment with Epothilone B at different concentrations, cells were centrifuged (1500
rounds per minute, 10’) in order to remove the medium. After this procedure they were
re-suspended in PBS (Phosphate buffered saline, a tampon solution), re-centrifuged and
then suspended in absolute ethanol (3 ml).
About 13 hours before cytofluorimetric analysis, the ethanol was removed through sam-
ple centrifuge; samples were then suspended in PBS and re-centrifuged. Cell pellet was
suspended with Ribonuclease A (100 µg/ml; SIGMA ALDRICH) and incubated at 37oC
for 30’. The use of this enzyme is necessary to degrade the RNA; in fact the fluorochrome
intercalating in RNA could affect the fluorescence measurements.
Samples were then re-centrifuged and suspended in Propidium Iodide (50 µg/ml; SIGMA
ALDRICH) (0.5 ml for samples with 5∗105 cells, 1 ml for samples with 106 cells) for about
12 hours.
Samples were then analyzed with the cytometer, in order to obtain fluorescence his-
tograms for cell cycle analysis. The analysis was performed through the software ModFit
LT.
First of all, a gate in the plane fluorescence signal area vs. fluorescence signal height was
applied in order to discard doublets and to select a correct cells population. An example
of gate is shown in figure 4.4.
After this gating, fluorescence histograms were analyzed to determine the percentage
of cells in each phase of the cycle and to individuate cells in apoptosis, when it occurs.
With the ModFit LT software it is possible to identify and symmetrize the fluorescence
peaks corresponding to the G1, G2 phase and apoptosis (when present). The percentage
of cells in each cycle phase is proportional to the correspondent area in the histogram.
The software calculates the areas of the G1, G2 and apoptosis peaks and expresses it as
a percentage of the total area. Considering that cells in the S phase have a DNA content
intermediate between G1 and G2, the software calculates the percentage of histogram
area corresponding to cells in S-phase.
Moreover, it calculates the ratio between the abscissa of the G2 and G1 peak; this value
can be used as a check for the analysis, in fact its value must be proximum to 2, consid-
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Figure 4.4: Example of gate to eliminate doublets in the cell cycle analysis. The cell population to
be analyzed must be close to the diagonal.
ering that in the G2 phase the DNA content is twice the G1 ones.
In figures from 4.5 to 4.8 the fluorescence histograms are displayed. Moreover, the
intensity of the G1, G2 and apoptosis (when present) peaks are reported, as well as the
ratio G2/G1, which represents the ratio between the abscissa of the G2 and G1 peaks.
It is possible to notice that at the concentrations chosen for our experiments (0.075 nM for
A549 cells and 0.125 nM for U251MG cells) very small variations in the G2 peaks occur
in respect with the control sample, but for U251MG cells an apoptosis peak is detected.
Despite we detect very small cell-cycle variations at these concentrations, in literature an
enhanced radiosensitivity in A549 cells pretreated with Epothilone B (0.075 nM) and ir-
radiated with photon beams was found (Baumgart et al., 2012a). Probably, this is due to
the fact that, even at low concentration, Epothilone B is able to modify DNA repair mech-
anisms, as mentioned in Chapter 3. Moreover, other mechanisms induced by Epothilone
B might be involved in radiosensitization.
The presence of the apoptosis peak shows that Epothilone B induces cell death via apop-
tosis; this cell-death mechanism is cell line dependent.
At the highest concentration studied (0.1 nM and 0.2 nM for A549 and U251MG cells,
respectively), an apoptosis peak is detected even for A549 cells and in U251MG cells the
apoptosis peak is more pronounced. Moreover in this cell line an higher G2 peak is de-
tected and the percentage of cells in the S phase increases while the G1 peak reduces.
We can observe that Epothilone B seems to weakly increase the number of cells in the
S-phase and this effect is more pronounced in the higher concentrations studied. Hof-
stetter et al. (2005) observed a supra-additive effect of Epothilone B combined with irra-
diation at concentrations that did not cause an accumulation of cells in the G2-M phase
and they found that Epothilone B treatment induces a transient accumulation of cells in
S phase, effect that became more marked when it is combined with irradiation. They
conclude that an accumulation of cells in S phase in combined treatment may indicate
that a decelerated S-phase transgression-related mechanism might cause the radiosensi-
tizing effect they observed for the combination of Epothilone B and irradiation.
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Figure 4.5: Cell cycle analysis through flow-cytometry of A549 cells (control sample and sample
treated with Epothilone B 0.05 nM).
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Figure 4.6: Cell cycle analysis through flow-cytometry of A549 cells (sample treated with
Epothilone B 0.075 and 0.1 nM).
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Figure 4.7: Cell cycle analysis through flow-cytometry of U251MG cells (control sample and sam-
ple treated with Epothilone B 0.075 nM).
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Figure 4.8: Cell cycle analysis through flow-cytometry of U251MG cells (sample treated with
Epothilone B 0.125 and 0.2 nM).
CHAPTER 5
Experimental Procedure
In this Chapter the experimental procedure followed to measure the effects of irradiation
with protons, carbon ions or photons combined with Epothilone B is described.
In figure 5.1, a very schematic description of the experimental procedure is displayed.
Before undergoing irradiation, cells and Epothilone B were prepared as described in Sec-
tion 5.1. The irradiation procedure followed with photon, proton or carbon ion beams is
described in Section 5.2; while Section 5.3 is dedicated to the treatments performed on
irradiated cells. The last Section is dedicated to the description of the assays performed
to investigate the different biological end points (clonogenic survival, invasive capacity
and cell growth).
Figure 5.1: Schematic description of the experimental procedure for the measure of the effects of
irradiation combined with Epothilone B.
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5.1 Cell culture and drug preparation
In order to prepare samples undergoing irradiation, we followed the procedure de-
scribed in this section.
As described in the previous Chapter, cells were stored in liquid nitrogen, in a so-
lution containing 40% of medium, 50% of fetal bovine serum and 10% of DMSO. After
thawing, cells were maintained at 37oC in humidified atmosphere containing 5% CO
2
.
48 hours before irradiation, cells were seeded in flasks T25 (growth area equal to 25
cm2) and maintained at 37oC in humidified atmosphere containing 5% CO
2
in air, as ex-
ponentially growing cultures in medium (DMEM for A549 cells and EMEM for U251MG
and DAOY cells), as described in Chapter 4.
24 hours before irradiation, a fraction of the cells was treated with Epothilone B at op-
portune concentrations (0.075 nM for A549 cells, 0.125 nM for U251MG cells and 0.035
nM for DAOY cells); the procedure followed for the drug preparation is fully described
in Chapter 4.
Just before irradiation, Epothilone B was removed and all the flasks were completely
filled with medium.
5.2 Irradiation
5.2.1 Photon Irradiation
Photon beam irradiation was performed using a 6 MV linear accelerator (VARIAN Clinac
2100C, Varian Medical Systems, Palo Alto, USA) at the Fondazione IRCCS Istituto Nazionale
dei Tumori, Milano. This linear accelerator is daily used for radiotherapy treatments.
Linear accelerators (LINAC) accelerate electrons, typically with voltage between 4 MV
and 25 MV, exploiting radiofrequency fields. Electrons are further accelerated through
waveguides and then they hit a Tungsten target, producing a bremmstrahlung photon
spectrum.
In order to compensate the Heel effect, according to which X-rays generated at greater
depth in the target undergo greater attenuation, compensation filters are used. Other
filters are used in order to eliminate the soft component of the photon beam and to uni-
form the photon beam intensity in the whole field size.
Beam homogeneity and delivered dose are monitored using ionization chambers.
In figure 5.2 a picture of the photon beam irradiation setting is shown.
The flasks containing cells undergoing irradiation were placed horizontally at the isocen-
ter in a water phantom at 5 cm depth and were irradiated using a vertical beam 20x20
cm2 field.
Samples were irradiated at different doses with a dose rate equal to 3 Gy/min.
Despite we used a maximum dose of 7 Gy for photon irradiation, we chose 5 Gy as
maximum dose for the irradiation of cells pretreated with Epothilone B, in order to ana-
lyze range of similar cytotoxicity for the standard treatment and for the combined one.
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Figure 5.2: Photon beam irradiation setting: Varian 2100C linear accelerator at the Fondazione
IRCCS Istituto Nazionale dei Tumori, Milano. The red circle points out the water phantom in
which the flasks are placed.
5.2.2 Hadrons Irradiation
Proton and carbon Ion beams irradiation was performed using the synchrotron-based
clinical scanning beams at the Centro Nazionale di Adroterapia Oncologica (CNAO),
Pavia (Rossi, 2015).
Beams features have been reported in a publication by Mirandola et al. (2015).
In this section a brief description of the main beam characteristic and of the configura-
tion used for sample irradiation will be given.
At CNAO proton and light ion beams can be provided. Particles are accelerated by a
synchrotron (figure 5.3) and an active scanning pencil beam technique is exploited.
The following information were taken from (Mirandola et al., 2015).
The scanning magnets are located 5.5 m from the isocenter, providing a small divergence,
so that CNAO beams are quasiparallel.
In treatment planning, the target volume is sectionated into isoenergy layers and the
desired dose at a given depth is delivered spot-by-spot, selecting the opportune energy.
For each energy layer two magnets scans the beam till all the spots are irradiated and
then they move to the following layer.
The maximum beam intensity that can be reached is equal to 3 ∗ 109 and 6 ∗ 107 particles
per second for protons and carbon ions, respectively.
Three treatment rooms are available, in the one we used for irradiation there is a single
horizontal fixed beam line.
As reported in table 2.1 in Chapter 2, the CNAO beams energy ranges from 62.73
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Figure 5.3: CNAO synchrotron (http://fondazionecnao.it).
to 228.57 MeV and 115.23 to 398.84 MeV/u for proton beams and carbon Ion beams,
respectively. Bragg peak widths are also reported in this table in terms of FWHM.
Spot size in air
The spot sizes (in terms of FWHM) resulted to be energy-dependent (FWHM decreases
with energy) and at the isocenter they vary from 2.2 to 0.7 cm for protons and from 0.8
to 0.4 cm for carbon Ions.
Moreover, the spot size dependence on its position resulted to be negligible.
Dose homogeneity
Dose homogeneity in 2D is evaluated in daily quality assurance along the main axes
and diagonals with EB3 films placed at the isocenter and irradiated with monoenergetic
uniform field (6 cm x 6 cm).
Homogeneity H is calculated as:
H = 100 ∗ Dmax −Dmin
Dmax +Dmin
were Dmax and Dmin are the maximum and the minimum measured dose.
Energy constancy
Energy constancy is daily monitored in quality assurance using radiochromic films placed
into solid slab phantom.
Irradiation configuration
The flasks containing cells undergoing irradiation were placed vertically inside a water
phantom, which was put at the isocenter on the treatment table (as shown in figure 5.4),
at the depth of 15 cm, corresponding to the mid Spread-Out Bragg Peak (SOBP). The
SOBP had a width of 6 cm (ranging from 12 to 18 cm depth) and it was obtained with
active beam energy modulation.
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Figure 5.4: Water phantom for cell irradiation in the treatment rooms at CNAO.
PROTONS IRRADIATION
Figure 5.5: Proton SOBP and dose-averaged LET as a function of depth, evaluated with a Monte
Carlo Fluka simulation. (Courtesy of Ciocca M., Mairani A. and Magro G. (CNAO))
The flasks were put in the center of an uniform scanned field. The field had a size of
10 x 10 cm2 and the scanning step was equal to 3 mm.
The SOBP was achieved using 16 different energies from 131.5 to 164.8 MeV.
The dose-averaged Linear Energy Transfer (LET) in the mid SOBP, evaluated with Monte
Carlo FLUKA simulation, was 3.6 keV/µm, as shown in figure 5.5. Samples were irradi-
ated at different doses (0-5 Gy). We chose 3 Gy as maximum dose for the irradiation of
cells pretreated with Epothilone B, in order to analyze range of similar cytotoxicity for
the standard treatment and for the combined one.
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carbon IONS IRRADIATION
Figure 5.6: carbon Ion SOBP and dose-averaged LET as a function of depth, evaluated with a
Monte Carlo Fluka simulation. (Courtesy of Ciocca M. and Mairani A. (CNAO))
The flasks were put in the center of an uniform scanned field. The field had a size of
10 x 10 cm2 and the scanning step was equal to 2mm.
The SOBP(uniform in physical dose) was achieved using 31 different energies from 246
to 312 MeV/u.
The dose-averaged Linear Energy Transfer (LET) in the mid SOBP, evaluated with Monte
Carlo FLUKA simulation, was about 45 keV/µm, as shown in figure 5.6.
Samples were irradiated at different doses (0-3 Gy). We chose 2 Gy as maximum dose for
the irradiation of cells pretreated with Epothilone B, in order to analyze range of similar
cytotoxicity for the standard treatment and for the combined one.
5.3 Post-irradiation treatments
Just after irradiation, the medium was removed and cells were detached from flasks us-
ing Trypsin-EDTA (0.25%). They were then counted using a portable Scepter cell counter
in experiments performed at CNAO, or a Beckmann Coulter Counter in experiments
performed at the Fondazione IRCCS Istituto Nazionale dei Tumori. The functioning of
these instruments for cell count is described in the next paragraph.
5.3.1 Instruments for cell count
Beckmann Coulter Counter
This instrument is based on the Coulter principle: suspended particles passing through
a pipe with an orifice produce an impedance variation when a voltage is applied.
Cells are suspended at low concentration in a solution containing an electrolyte.
Specifically, 0.5 ml or 1 ml cell suspension is added to 19.5 ml or 19 ml of Isoton (dilution
factor 40 or 20). A thin tube containing two electrodes is immersed in this solution; in the
tube a small hole is present. In figure 5.7 a picture of the tube immersed in the solution
Experimental Procedure 51
is shown.
Figure 5.7: Beckmann Coulter Counter. The tube is immersed in the glass containing the isotonic
solution with cells to be counted.
The sensitive volume of the instrument is between the two electrodes, which in the pres-
ence of current provide an impedance measure. The solution is aspirated within the
sensitive volume: the passage of a cell in this region induces an impedance variation, in
fact the cell double lipid membrane opposes to the current passage.
Each impedance variation is recorded as a count and the amplitude of the signal is pro-
portional to the cell volume. It is possible to set a gate on volumes, excluding impedance
variations that may not be due to the passage of a cell (for example due to debris pas-
sage).
The instrument calculates the cell density (cell/ml) as the average value of the counts
made on the solution.
Scepter Handheld Automated Cell Counter
The functioning of this instrument is the same of the Beckmann Coulter Counter. The
main advantage is the small dimension, that permits to carry the instrument in other
laboratories.
The sensitive volume in this case is a tip, that is immersed in a pipe containing cells to
be counted. After the counting the tip must be discarded.
Also in this instrument it is possible to set a gate in order to exclude counting not asso-
ciated to a cell passing within the sensitive volume.
In figure 5.8 a picture of the Scepter Handheld Automated Cell Counter is shown.
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Figure 5.8: Scepter Handheld Automated Cell Counter used during an experiment at CNAO.
After counting, cells were prepared for the study of different biological end points,
as described in the following section.
5.4 Biological end-points
In the present study, we investigated different biological end-points: cell clonogenic
survival, invasive capacity and cell growth of irradiated cells pretreated or not with
Epothilone B at the chosen concentrations.
Invasion rate and cell growth were investigated only for A549 and U251MG cells and for
carbon Ions and Photons irradiation.
In the following paragraphs the assays performed for the study of these end-points will
be described.
5.4.1 Clonogenic survival assay
Clonogenic (colony forming) assay is widely applied in order to study cell proliferative
capacity. The original paper by Puck and Marcus (1956) described the technique for this
assay.
For the measure of clonogenic survival, irradiated cells were plated into five flasks T25
for each dose at different inocula, calculated considering the expected survival that was
estimated taking into account the dose and the Epothilone B concentration.
After seeding, cells were incubated for about 13 days and after this period they were
fixed with ethanol, stained with 10% Giemsa solution and counted.
Colonies consisting of more than 50 cells were scored as survivors. An example of
colonies generated from survived cells after the fixing and staining procedure is dis-
played in figure 5.9.
For each dose, the number of survived cells was determined as the mean of the counts
obtained for the five flasks. The plating efficiency PE was then determined as the ratio
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Figure 5.9: Colonies generated from survived cells after the fixing and staining procedure.
between the mean number of survived cells and the number of cells initially plated.
Surviving fractions at dose D (S(D)) were determined as the ratio between the plating
efficiency (PE(D)) of the irradiated sample and the control one (PE(0)):
S =
PE(D)
PE(0)
.
Survival curves for irradiated cells (pretreated or not with Epothilone B) were ob-
tained plotting the surviving fraction as a function of dose.
At least three independent experiments have been performed for each radiation type
and cell line. The final survival values were obtained as the mean of the surviving frac-
tions measured in each experiment.
An example of survival data for cells irradiated with photons, pretreated or not with
Epothilone B, is reported in figure 5.10.
5.4.2 Cell invasion assay
Cell invasion was investigated only in A549 and U251MG cells pretreated or not with
Epothilone B and irradiated at three doses: 0 Gy, 1.5 Gy and 3 Gy for photon beams, 0
Gy, 0.75 Gy and 1.5 Gy for carbon Ions.
Cells invasion rate was measured using the CHEMICON Cell Invasion Assay Kit (QCM
ECMatrix Cell Invasion Assay, Merck-Millipore).
After irradiation, about 106 cells were plated in each insert in serum-free medium. In the
lower chamber of every insert 500µl of medium containing 10% fetal bovine serum were
dropped.
The inserts contain an 8µm pore size polycarbonate membrane, over which a layer of
ECMatrixTM is deposited. This thin layer occludes the membrane pores, preventing
non-invasive cells from migrating, while invasive cells can migrate through the ECMa-
trix layer, reaching the bottom of the polycarbonate membrane in about 24 hours, as
shown in figure 5.11.
After 24 hours of incubation, non-invasive cells and the ECMatrix were removed
from the interior of the insert, while the invasive cells (migrated to the bottom of the
membrane) were stained with Chrystal Violet stain and then counted by photographing
the membrane through a microscope.
The invasion rate has been determined as the ratio between the invasive counted cells
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Figure 5.10: Surviving fraction of A549 cells as a function of dose for cells pretreated or not with
Epothilone B.
Figure 5.11: Schematic description of the invasion assay.
and the total number of plated cells. Values obtained for cells irradiated and/or treated
with Epothilone B were then normalized to the control one, in order to obtain the relative
invasion rate.
At least two independent experiments have been performed.
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5.4.3 Cell growth
Cell growth was measured only in U251MG cells pretreated or not with Epothilone B
and irradiated with carbon ion beams at three doses: 0 Gy, 0.75 Gy and 1.5 Gy.
Just after irradiation cells were plated at different inocula in flasks T25 and then incu-
bated.
At different time from irradiation cells were detached from flasks using Trypsin-EDTA
(0.25%). They were then counted using a Beckmann Coulter Counter.
Growth curves were obtained plotting the ratio between the number of counted cells n(t)
and the number of cells initially plated n0 as a function of time.
Two independent experiments have been performed.

CHAPTER 6
Data analysis
The aim of this thesis is the study of the effects obtained combining radiations and
Epothilone B in human cancer cell cultured in vitro, investigating different biological
end-points.
In particular, the main goal of this study is to determine if the Epothilone B has a ra-
diosensitising effect when combined with photon, proton or carbon ion irradiation.
In this Chapter the analysis of data relative to cell clonogenic survival, Relative Biologi-
cal Effectiveness, cell invasive capacity, and cell growth will be described.
Moreover, the analysis of the radiation-drug interaction performed in order to determine
if radiation and Epothilone B interact in an additive way, or in a synergic one will be ex-
plained.
The procedures described in the following sections were applied to the data obtained for
all cell lines and radiation types. For brevity, in this Chapter only the analysis performed
on A549 cells (or U251MG cells in the case of cell growth) will be described, by way of
example. The results obtained for all cell lines and radiations will be exposed in Chapter
7.
In the first section the analysis of surviving fraction performed to obtain the survival-
dose curves will be shown. Afterwards, the procedure followed to determine the Rela-
tive Biological Effectiveness will be described. In the third section the analysis of radiation-
drug interaction according to the model of Luttjeboer et al. (2010) will be presented. Sec-
tion 4 and 5 will be dedicated to the analysis of cell invasive capacity and growth.
6.1 Survival curves
The mean surviving fractions obtained as described in Chapter 5 and plotted as a func-
tion of dose were used to determine dose-survival curves. It was estimated that an error
on survival lower than 10% could underestimate the real uncertainty in clonogenic sur-
vival measurements, given the biological variability and the uncertainties in the post-
irradiation treatments and on the inoculum. Thus, the error on survival was determined
as the greatest value between the standard error of the mean and the 10% of the survival
value:
σS = max
√∑Ni=1(Si− < S >)
N(N − 1) ; 10%

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Given the great uncertainties on surviving fractions, the uncertainties on the ab-
sorbed dose were considered to be negligible.
Survival data as a function of radiation dose were fitted with the software OriginLab
according to the Linear Quadratic (LQ) model (described in Chapter 1) for all cell lines
and radiations type. A weighted fit was performed using error bars as weight: wi =
1
σ2i
.
More details about the fit are exposed in Appendix A.
The obtained curves were exploited for RBE determination and for the analysis of
radiation-drug interaction mechanism.
Figure 6.1: Survival curves of A549 cells pretreated (empty circles) or not (full circles) with 0.075
nM Epothilone B and irradiated with photon beams. Reported data are the mean of 5 independent
experiments.
In figure 6.1 survival curve of A549 cells exposed to radiation alone (full circles) and
combined with 0.075 nM Epothilone B (empty circles) are reported, as an example.
The curve relative to radiation alone represents the interpolation of the experimental
points according to the linear quadratic model:
S = e−αD−βD
2
(6.1)
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where S is the Surviving fraction and D the radiation dose.
We can observe that data relative to cells treated with Epothilone B and then irradiated
show a different radiation dose-dependence: surviving fraction exponentially decreases
with dose, without any shoulder. In fact, the β parameter of the LQ fit is consistent with
0. Thus data are interpolated with a linear function:
S = S0e
−αD (6.2)
The parameter S0 represents the clonogenic survival of cells treated with Epothilone B
and not irradiated.
Analogous results were found with proton beams and for all the cell lines, while, as
expected, survival curves relative to cell simply irradiated with carbon Ions shows a lin-
ear trend , the β parameter being negative. The obtained results will be presented and
discussed in the next Chapter.
6.2 Relative Biological Effectiveness (RBE)
RBE (defined in Chapter 1) was calculated as the ratio between the dose of reference ra-
diation (6MV photons) and that of protons or carbon Ions necessary to produce the same
biological effect. The end-point we decided to use for RBE determination is the 10% of
survival. RBE was calculated as the ratio between the doses of photons and that of pro-
tons or carbon Ions that lead to a surviving fraction equal to 0.1, as displayed in figure
6.2, where the surviving fractions of A549 cells exposed to photons (circles) or protons
(triangles) are shown.
RBE at 10% of survival (RBE10%) was calculated according to equation 6.3.
RBE10% =
(
Dphotons
Dradiation
)
S=0.1
(6.3)
The radiation doses D0.1 necessary to obtain a surviving fraction of 0.1 were calculated
starting from the survival curves, according to equation 6.4 and 6.5 for linear-quadratic
curves and linear curves, respectively.
D0.1 =
−α+√α2 − 4βln(0.1)
2β
(6.4)
D0.1 =
−α
ln(0.1)
(6.5)
RBE uncertainty was determined according to error propagation:
σRBE10% =
√(
∂RBE10%
∂Dphotons
)2
σ2Dphotons +
(
∂RBE10%
∂Dradiation
)2
σ2Dradiation
= RBE10%
√(
σDphotons
Dphotons
)2
+
(
σDradiation
Dradiation
)2 (6.6)
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Figure 6.2: Surviving fractions of A549 cells exposed to photons (circles) or protons (triangles) are
shown. 10% of survival and the dose of photons and protons that lead to this survival level are
highlighted in order to show the procedure followed to calculate the RBE10%.
Dose uncertainties are determined according to error propagation through relations
6.7 and 6.8 for linear quadratic curves and linear curves, respectively.
σD =
√(
∂D
∂α
)2
σ2α +
(
∂D
∂β
)2
σ2beta + 2cov(α, β)
∂D
∂α
∂D
∂β
(6.7)
σD =
∂D
∂α
σα (6.8)
where α and β are the fit parameters and D the dose of radiation.
In equation 6.7 the covariance of α and β appears, since the parameter of the linear
quadratic fit cannot be considered completely uncorrelated. cov(α, β) resulted to be al-
ways negative for all the linear quadratic curves. The fact that the covariance is negative
is coherent with the fact that α and β are weakly anti-correlated, since when α increases
β decreases and viceversa.
We can notice that the product
∂D
∂α
∂D
∂β
is negative. In fact, the partial derivatives of dose
D with respect to α and β are:
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∂D
∂α
= − D
α+ 2βD
∂D
∂β
= − D
2
α+ 2βD
.
Thus, the product of the two derivatives is:
∂D
∂α
∂D
∂β
=
D3
(α+ 2βD)
2 > 0
As a consequence, the product 2cov(α, β)
∂D
∂α
∂D
∂β
is negative, given the values of
cov(α, β), and can lead to an underestimation of the real RBE uncertainties. For this
reason, we decided to neglect this term in the calculation of doses uncertainties, consid-
ering the parameters α and β as independent .
6.3 Radiation-drug interaction mechanism
As mentioned in Chapter 3, the model proposed by Luttjeboer et al. (2010) was applied
in order to analyze radiation-drug interactions, basing on changing in clonogenic capac-
ity induced by radiation modifying agents, like Epothilone B.
Different quantitative analysis of dose-effects relations have been published, for our
analysis we decided to exploit this model because it is the nearest to our experimen-
tal approach.
This model started from the analysis of Lam (1989) in which the final effect of the com-
bination of two cytotoxic agents on the biological system is produced in a certain time
through a series of intermediate lesions. As a consequence, two extreme definition of
additivity are proposed: on the one hand, two additive cytotoxic agents can act through
completely independent mechanism, while, on the opposite, they can act mainly in the
same way, causing the same intermediate lesions. A schematic description of this two
additive modalities of interaction is given in figure 6.3. In the first case (a) agents A and B
product different intermediate lesions leading to the final effect AB. In case b, the agents
A and B products the same kind of intermediate lesions, leading to the final effect AB.
Figure 6.3: Schematic description of the Lam approach.
Basing on this approach, in the model Luttjeboer et al. (2010) an area of additiv-
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ity is built in the survival-dose plane. This region is delimited by two curves obtained
supposing two different modalities of additivity between cytotoxic agents: the indepen-
dent and the overlapping additivity. In the independent additivity, the only action of the
chemotherapy is the reduction of the number of clonogenic cells on which radiation will
act and drug and radiation act completely independently. Thus, the final surviving frac-
tion is simply the product of the surviving fractions obtained exposing cells to radiation
and drug separately. Looking at the survival curves, this action cause a downward shift
of starting point of the survival curve relative to irradiation alone. The curve of indepen-
dent additivity is so built starting from survival curve for irradiation alone, according to
equation 6.9.
S = S0e
−αD−βD2 (6.9)
Where S0 is the surviving fraction of cells treated with Epothilone B and not irradiated,
used as starting point for the irradiation, while α and β are the parameter of the survival
curve of cells just irradiated, reported in equation 6.1.
In the case of overlapping additivity, the drug is supposed to act as an additional radia-
tion dose, D?, defined as the radiation dose giving a citotoxicity equal to that obtained
with the drug alone (i.e. leading to a surviving fraction equal to S0). Looking at survival
curves, the overlapping additivity reflects in a left-shift of the survival curve relative to
irradiation alone. Thus, the curve of overlapping additivity is built starting from sur-
vival curve for irradiation alone, according to equation 6.10.
S = e−α(D+D
?)−β(D+D?)2 (6.10)
α and β are the parameter of the survival curve of cells just irradiated, reported in equa-
tion 6.1, while D? is calculated from survival curve for irradiation alone, imposing a
surviving fraction equal to S0: {
S = e−αD−βD
2
S = S0
D? =
−α+√α2 − 4ln(S0)β
2β
(6.11)
Experimental curves obtained for the radiation-drug combination falling within the ad-
ditivity area (delimited by the independent and overlapping additivity curves) indicate
a simply additive interaction between the two agents, otherwise experimental data that
fall below this region, indicate a synergic interaction.
α 0.343 Gy−1
β 0.028 Gy−2
S0 0.390
D? 2.31 Gy
Table 6.1: Parameters used to calculate the independent and overlapping additivity curves for
A549 cells irradiated with photon beams.
In figure 6.4 the analysis of interaction of photon beams and Epothilone B (0.075 nM)
according to the described model is displayed for A549 cells, as an example. The relative
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Figure 6.4: Analysis of the interaction between photons and Epothilone B (0.075 nM) in A549 cells.
The region of ”partial common action” (corresponding to an additive interaction) is bounded by
the independent (red, dashed line) and overlapping (green, dotted line) curves. These curves were
built shifting downwards or on the left the curve relative to irradiation alone (orange, solid line).
The curve relative to the combined treatment of photons and Epothilone B (black, solid line) that
fits the experimental data (empty circles) falls below the additivity region, indicating a synergism
in radiation-drug interaction.
survival curves are shown in figure 6.1. We can notice that the experimental points and
the curve relative to irradiation combined to the Epothilone B treatment fall below the
additivity region delimited by the red (independent) and the green (overlapping) curves,
indicating a synergic interaction modality. The overlapping curve is parallel to the curve
relative to irradiation alone, while the independent curve seems to have a different slope,
due to the presence of the factor S0 in equation 6.9. It is important to underline that in
this representation a different slope with respect to that of irradiation alone does not in-
dicate a non-additive interaction.
In table 6.1 the values of the parameter used to calculate the independent and overlap-
ping additivity curves (according to equations 6.9 and 6.10) are reported.
In case of linear curve relative to irradiation alone, like for high-LET radiation sur-
vival curves (S = e−αD), the independent and the overlapping curves, calculated ac-
cording to equations 6.9 and 6.10 with β = 0, coincide and the area of partial common
action degenerates in a straight line, below which the radiation-drug interaction can be
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considered synergic.
In order to quantify the effectiveness of the combined treatment with respect to irra-
diation alone, the Dose Enhancement Factor (DEF), was determined. The DEF is defined
as the ratio between the radiation doses used alone (Dir) and combined to the drug
(Dir+drug) to obtain the same biological end point (i.e. the same survival level). It is im-
portant to highlight that with linear-quadratic survival curves a DEF value greater than
1 is not an indication of a synergistic interaction according to the model we applied, but
simply a quantification of the greater effectiveness of the combined treatment with re-
spect to irradiation alone.
We calculated the DEF at 10% of survival for all radiation types and cell lines:
DEF10% =
(
Dir
Dir+drug
)
S=10%
Figure 6.5: Example of DEF calculation.
For this calculation the curve relative to the combined treatment was normalized to the
surviving fractions of cells pretreated with Epothilone B and not irradiated (S0), in order
to compare this curve with the one relative to irradiation alone, as shown in figure 6.5.
Results obtained for all radiation types and cell lines are reported in Chapter 7.
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6.4 Invasion rate
Figure 6.6: Relative Invasion Index of A549 cells irradiated with photons at different doses pre-
treated or not with Epothilone B 24 hours before irradiation. (I.I. values have been normalized to
the control sample).
As described in the previous Chapter, Invasion Index (I.I.) was measured as the ratio
between the number of invading cells, passed through the ECMatrix, and the total num-
ber of seeded cells. Obtained I.I. values were then normalized to the control sample, in
order to obtain the relative invasion index for every dose for both Epothilone B treated
and untreated samples.
Results were plotted in histograms, as the one reported in figure 6.6 in which the relative
I.I. of A549 irradiated with photon beams combined to 0.075 nM Epothilone B or not is
reported.
Error bars were determined as the greatest value between the standard error and 10% of
the relative I.I., as in the case of Surviving fractions, due to analogous considerations.
6.5 Cell growth
Cell growth was measured only for U251MG cells irradiated with carbon ions.
The mean ratio between the number of cells counted at time t n(t) and the number of
plated cells n0 has been plotted as a function of time for each dose of radiation combined
to Epothilone B or not. In order to calculate the uncertainties on time and on the ratio
n(t)
n0
the standard error was calculated.
Obtained curves were then compared with the aim of evaluating the effects of irradia-
tion and Epothilone B on cell growth.
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Data relative to cells in the phase of exponential growth were then fitted according
to equation 4.1. Looking at data relative to cells irradiated with carbon ions, we noticed
a delay in the growth curves which resulted shifted with respect to the curve relative to
the control sample. In this case, data were fitted according to equation 6.12
n(t)
n0
= 2
(t− x)
tD (6.12)
where x is the delay and tD the doubling time.
Also in this case, error bars were determined as the greatest value between the standard
error and 10% of the relative I.I., as in the case of Surviving fractions, due to analogous
considerations.
Weighted fits were performed with the software OriginLab. Details on the fitting proce-
dure with this software are reported in Appendix 3.
CHAPTER 7
Experimental results: description and interpretation
In this Chapter the results obtained after the analysis presented in Chapter 6 will be de-
scribed and discussed.
First of all, dose-survival curves will be shown for cells irradiated, treated or not
with Epothilone B and a comparison between the effects induced by photons, protons
and carbon ions will be performed. Then, the values obtained for proton and carbon
ion Relative Biological Effectiveness will be presented and discussed. The results of the
analysis of radiation-drug interaction will be then described and commented. Data ob-
tained in experiments with photon and proton beams on A549 and U251MG cells have
been reported in an already submitted paper (Bettega et al.).
In the following sections, results obtained on cell growth and invasion will be described
for cells irradiated and exposed or not to Epothilone B.
7.1 Dose-survival curves
Dose-survival curves will be presented for each cell line, comparing the results obtained
with the different radiation types combined or not with Epothilone B. Data are reported
in semilogarithmic plots and error bars were estimated following the procedure de-
scribed in Chapter 6.
In the following paragraphs survival data (mean of at least 3 independent experiments)
of A549, U251MG and DAOY cells exposed to 6MV LINAC photon, proton (dose-averaged
LET = 3.6keV/µm) or carbon ion (dose-averaged LET = 45keV/µm) beams pretreated or
not with Epothilone B will be displaied. The reported curves are the fit to the experimen-
tal points according to the LQ model (equations 6.1 and 6.2 for cells simply irradiated or
even treated with the drug, respectively). The fit parameters are reported in table 7.4.
7.1.1 A549 cells
Figure 7.1 shows survival curves of A549 cells simply irradiated. As expected, the curve
relative to C-ions irradiation is linear, in fact the β parameter in equation 6.1 is negative.
A negative β-value has no physical meaning according to the LQ model, for this reason
data were fitted with a pure exponential function (imposing β = 0). This behavior is
typical of cells irradiated with High-LET radiation.
Looking at survival curves relative to photon and proton irradiation, we can notice that
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the latter are more effective in inducing clonogenic cell death; this fact reflects on a pro-
ton RBE value higher than 1 (more details are discussed in Section 7.2).
Figure 7.2 shows survival data of A549 cells pretreated with 0.075 nM Epothilone B
and irradiated. We can observe that data obtained for cells treated with Epothilone B
and irradiated with photons or protons show a dose dependency different from the one
of cells simply irradiated. In fact, the surviving fraction decreases exponentially with
dose, without any shoulder. This is a first clue of the fact that Epothilone B modifies
cell response to irradiation, removing the shoulder (described by the quadratic term in
equation 6.1) typical of low-LET irradiation. This aspect will be investigated in Section
7.3.
In table 7.1 the mean surviving fractions are reported for each dose. Data collected in
each experiment are reported in Appendix C.
Irradiation
photon irradiation proton irradiation C-ion irradiation
Dose [Gy] S error Dose [Gy] S error Dose [Gy] S error
0 1.00 0.10 0 1.00 0.10 0 1.00 0.1
0.5 0.84 0.08 0.5 0.87 0.09 0.5 0.57 0.06
1 0.66 0.07 1 0.56 0.06 0.75 0.30 0.05
2 0.49 0.05 2 0.25 0.02 1 0.15 0.02
3 0.25 0.03 3 0.13 0.01 1.5 0.071 0.007
5 0.10 0.01 4 0.05 0.00 2 0.031 0.003
7 0.022 0.002 5 0.03 0.01 3 0.010 0.001
Irradiation + Epothilone B
Dose [Gy] S error Dose [Gy] S error Dose [Gy] S error
0 0.41 0.04 0 0.39 0.04 0 0.40 0.04
0.5 0.30 0.03 0.5 0.26 0.03 0.5 0.20 0.02
1 0.19 0.02 1 0.12 0.01 0.75 0.10 0.01
2 0.091 0.009 2 0.062 0.006 1 0.05 0.01
3 0.042 0.004 3 0.023 0.003 1.5 0.026 0.007
5 0.014 0.001 4 0.012 0.002 2 0.009 0.002
Table 7.1: Mean surviving fractions of A549 cells irradiated with photon, proton and carbon ion
beams with or without 0.075 Epothilone B.
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Figure 7.1: Surviving fraction of A549 cells exposed to photons (mean of 5 independent experi-
ments), protons (mean of 4 independent experiments) and carbon ions (mean of 3 independent
experiments). Solid lines are the fit of the experimental data according to equations 6.2. In the
case of C-ions irradiation the quadratic term was set to 0. Error bars represent the maximum value
between the Standard Error and the 10% of Survival.
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Figure 7.2: Surviving fractions of A549 cells pretreated with 0.075 nM Epothilone B and exposed
to photons (mean of 5 independent experiments), protons (mean of 3 independent experiments)
and carbon ions (mean of 3 independent experiments). Solid lines are the fit of the experimental
data according to equations 6.2. Error bars represent the maximum value between the Standard
Error and the 10% of Survival.
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7.1.2 U251MG cells
Figures 7.3 and 7.4 show survival curves of U251MG cells simply irradiated or irradiated
and pretreated with 0.125 nM Epothilone B, respectively.
Considerations analogue to those relative to A549 cells can be done.
In table 7.2 the mean surviving fractions are reported for each dose. Data collected in
each experiment are reported in Appendix C.
Irradiation
photon irradiation proton irradiation C-ion irradiation
Dose [Gy] S error Dose [Gy] S error Dose [Gy] S error
0 1.0 0.1 0 1.0 0.1 0 1.0 0.10
0.5 0.90 0.09 0.5 0.80 0.08 0.5 0.61 0.07
1 0.72 0.07 1 0.53 0.05 0.75 0.35 0.04
2 0.48 0.05 2 0.25 0.03 1 0.17 0.02
3 0.22 0.02 3 0.10 0.01 1.5 0.09 0.01
5 0.07 0.02 4 0.043 0.004 2 0.041 0.004
7 0.019 0.004 5 0.011 0.001 3 0.012 0.002
Irradiation + Epothilone B
Dose [Gy] S error Dose [Gy] S error Dose [Gy] S error
0 0.411 0.041 0 0.41 0.04 0 0.42 0.04
0.5 0.241 0.024 0.5 0.23 0.03 0.5 0.24 0.04
1 0.127 0.013 1 0.11 0.02 0.75 0.13 0.02
2 0.064 0.006 2 0.043 0.004 1 0.050 0.007
3 0.029 0.003 3 0.015 0.001 1.5 0.023 0.003
5 0.007 0.001 4 0.0059 0.0006 2 0.0082 0.0008
Table 7.2: Mean surviving fractions of U251MG cells irradiated with photon, proton and carbon
ion beams with or without 0.125 Epothilone B.
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Figure 7.3: Surviving fractions of U251MG cells exposed to photons (mean of 4 independent ex-
periments), protons beams (mean of 4 independent experiments) and carbon ions (mean of 3 inde-
pendent experiments). Solid lines are the fit of the experimental data according to equations 6.2.
In the case of C-ions irradiation the quadratic term was set to 0. Error bars represent the maximum
value between the Standard Error and the 10% of Survival.
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Figure 7.4: Surviving fractions of U251MG cells pretreated with 0.125 nM Epothilone B and ex-
posed to photon (mean of 3 independent experiments), proton beams (mean of 4 independent
experiments) and carbon ions (mean of 3 independent experiments). Solid lines are the fit of the
experimental data according to equations 6.2. Error bars represent the maximum value between
the Standard Error and the 10% of Survival.
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7.1.3 DAOY cells
DAOY cells were treated only with low-LET radiation (protons and photons), as men-
tioned in the previous chapters. Figure 7.5 shows survival data of DAOY cells simply
irradiated. We can notice that this cell line is more radiosensitive than the A549 and the
U251MG and that protons and photons survival curves are quite similar. This behavior
is typical of very radiosensitive cell-lines.
Figure 7.6 shows survival data of cells pretreated with 0.035 nM Epothilone B and irra-
diated.
We can observe that also in this cell line, Epothilone B remove the dose-survival curve
shoulder, modifying cell response to irradiation. Moreover, due to the high radiosen-
sitity of this cells even to photon irradiation, the curves relative to the combination of
protons or photons to Epothilone B are very similar.
In table 7.3 the mean surviving fraction are reported for each dose. Data collected in
each experiment are reported in Appendix C.
Irradiation
photon irradiation proton irradiation
Dose [Gy] S error Dose [Gy] S error
0 1 0.1 0 1 0.1
0.5 0.83 0.08 0.5 0.80 0.08
1 0.70 0.07 1 0.55 0.06
2 0.37 0.04 2 0.26 0.03
3 0.17 0.02 3 0.13 0.01
5 0.041 0.004 4 0.058 0.006
7 0.010 0.001 5 0.022 0.002
Irradiation + Epothilone B
Dose [Gy] S error Dose [Gy] S error
0 0.42 0.04 0 0.39 0.04
0.5 0.27 0.03 0.5 0.27 0.03
1 0.13 0.01 1 0.13 0.01
2 0.053 0.005 2 0.062 0.006
3 0.025 0.002 3 0.025 0.002
5 0.005 0.002 4 0.013 0.004
Table 7.3: Mean surviving fractions of DAOY cells irradiated with photon and proton beams with
or without 0.035 Epothilone B.
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Figure 7.5: Surviving fractions of DAOY cells exposed to photon (mean of 3 independent exper-
iments) and proton beams (mean of 4 independent experiments). Solid lines are the fit of the
experimental data according to equations 6.1. Error bars represent the maximum value between
the Standard Error and the 10% of Survival.
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Figure 7.6: Surviving fractions of DAOY cells pretreated with 0.035 nM Epothilone B and exposed
to photon (mean of 3 independent experiments) and proton beams (mean of 4 independent ex-
periments). Solid lines are the fit of the experimental data according to equations 6.2. Error bars
represent the maximum value between the Standard Error and the 10% of Survival.
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Fit Parameters
Parameter A549 U251MG DAOY
Photon irradiation
α[Gy−1] 0.34 ± 0.04 0.38 ± 0.04 0.51 ± 0.04
β[Gy−2] 0.028 ± 0.009 0.028 ± 0.006 0.022 ± 0.007
Photon irradiation + Epothilone B
S0 0.39 ± 0.03 0.34 ± 0.02 0.38 ± 0.03
α[Gy−1] 0.70 ± 0.04 0.82 ± 0.04 0.94 ± 0.04
Proton irradiation
α[Gy−1] 0.56 ± 0.07 0.54 ± 0.05 0.57 ± 0.05
β[Gy−2] 0.05 ± 0.02 0.07 ± 0.01 0.04 ± 0.01
Proton irradiation + Epothilone B
S0 0.36 ± 0.03 0.38 ± 0.03 0.37 ± 0.03
α[Gy−1] 0.89 ± 0.04 1.06 ± 0.03 0.90 ± 0.04
C-ions irradiation
α[Gy−1] 1.69 ± 0.03 1.57 ± 0.03 /
C-ions irradiation + Epothilone B
S0 0.43 ± 0.03 0.44 ± 0.04 /
α[Gy−1] 1.9 ± 0.1 1.99 ± 0.07 /
Table 7.4: Dose-survival curve parameters of A549, U251MG and DAOY cells irradiated with
photons, protons or carbon ions combined or not with Epothilone B.
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7.2 Relative Biological Effectiveness
Proton and C-ion RBE was calculated according to equation 6.3 starting from dose-
survival curves using a survival level of 10% as end point, as described in the previous
Chapter. In this Section, the RBE values obtained for protons and C-ions will be pre-
sented and compared with values published in literature.
7.2.1 Proton RBE
Proton (dose-averaged LET 3.6 keV/µm) RBE was calculated using 6MV LINAC photon
beams as reference radiation and resulted to be cell line dependent. The doses of pho-
tons and protons producing a surviving fraction equal to 10% are 4.82 and 3.22 for A549
cells, 4.56, 3.06 for U251MG cells and 3.88 and 3.31 for DAOY cells. In table 7.5 proton
RBE10% values for A549, U251MG and DAOY cells are reported.
Cell line RBE
A549 1.5 ± 0.2
U251MG 1.5 ± 0.2
DAOY 1.2 ± 0.1
Table 7.5: proton RBE10% for A549, U251MG and DAOY cells.
A549 and U251MG cell RBE is greater than the value nowadays assumed in proton
therapy, equal to 1.1 (ICRU, 2007), while the RBE value obtained for DAOY, is compati-
ble with the clinical value. The proton RBE value 1.1 represents the mean value derived
from widely different datain vitro and in vivo data. In vitro measured values of proton
RBE show significant variations as reported in reviews by Jones (2016) and Paganetti
(2014), ranging from 0.9 to 2.1 (Paganetti et al., 2002). These RBE variations may be due
to different experimental conditions (beam energy, active scanning techniques or passive
beam modulation, methods for RBE calculation, cell lines, reference radiation). Recent
reviews indicate that for many end points cell biological response is differently modu-
lated by proton or photon irradiation (Tommasino and Durante, 2015; Girdhani et al.,
2013). Recently, many results concerning the differences in DSB induction and repair
between photon and proton irradiation have been reported in literature; in particular it
was found that proton irradiation induces an increased number of DSBs and Clustered
Lesions when compared to photons (137Csγ rays) (Calugaru et al., 2011). Moreover, re-
cent studies investigated the impact of homologous and nonhomologous end-joining
pathways in repairing DSB after photon or charged particle irradiation: it was reported
that proton-induced DSBs preferentially follow the homologous-recombination repair
pathway in A549 and glioblastoma cells(Fontana et al., 2015); this pathway is believed
to be followed in the repair of more complex lesions.
In addition, it is known that the biological effect of irradiation are also influenced by free-
radicals production, in particular Reactive Oxygen Species (ROS): Mitteer et al. (2015)
showed that when compared to photons, protons induce greater cytotoxicity, DNA dam-
ages and cell cycle alteration through ROS in glioma stem cells.
For all this reason, proton RBE is still widely studied and debated.
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The RBE value we measured for DAOY cells does not significantly differ from the
clinically assumed value. We conjecture that this different behavior with respect to A549
and U251MG cells is due to the different radiosensitivity of these cell lines. As a matter
of fact, DAOY cells resulted to be more radiosensitive, as shown in the dose-survival
curves reported in the previous section. Thus, it is probable that in this cell line the DNA
repair mechanisms are less efficient than in A549 and U251MG cells.
Combined treatment biological effectiveness
For the combination of irradiation and Epothilone B, proton effectiveness relative to pho-
tons was calculated as the ratio between the slopes of the two combined treatment sur-
vival curves (
αp
αX
). Since the curves are exponential, this ratio did not depend on the
survival level and its value resulted 1.3 ± 0.1 for A549 and U251MG cells, suggesting
that the combination of Epothilone B with proton beams can lead to a greater effective-
ness with respect to its combination with photon beams.
The relative effectiveness in DAOY cells resulted equal to 0.96 ± 0.06, indicating that for
this cell line there are no significative differences in therms of treatment efficacy when
Epothilone B is combined with photon or proton beams.
7.2.2 C-ion RBE
C-ion (dose-averaged LET 45 keV/µm) RBE was measured only for A549 and U251MG
cells using 6MV LINAC photon beams as reference radiation and resulted to be cell line
dependent. In table 7.6 the obtained RBE10% values at the mid SOBP are reported.
The doses of photons and carbon ions producing a surviving fraction equal to 10% are
4.82 and 1.46 for A549 cells 4.56 and 1.46 for U251MG cells.
Cell line RBE
A549 3.5 ± 0.3
U251MG 3.1 ± 0.3
Table 7.6: C-ion RBE10% for A549 and U251MG cells.
In literature different carbon ion RBE values are reported ranging from 2 to 5. C-ion
RBE varies with LET, as mentioned in Chapter 1. Moreover differences in RBE values
can be caused by different experimental conditions (beam line, active or passive beam
modulation and so on). It is important to underline that, as previously reported, carbon
ions effectiveness is much greater than that of photons in the Bragg Peak region, where
the LET increases.
Schlaich et al. (2013) using a SOBP carbon ion beam (rasterscanning technique, dose-
averaged LET 103 keV/µm) found that C-ions RBE at 10% of survival is equal to 3.6 ±
0.8 in A549 cells. Niemantsverdriet et al. (2011) using a 90 MeV/u carbon ions (dose-
averaged LET equal to 189 keV/µm) and γ produced by a 137Cs source as reference
radiation found that A549 RBE at 10% of survival is equal to 3.4. These RBE values are
compatible with the one we measured for the same cell line, but in our measurements
the dose-averaged LET is smaller, so that it is difficult to compare this values.
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Tsuboi et al. (1998), using a monoenergetic carbon ion beam and γ rays from 137Cs
as reference radiation, measured the RBE of different glioblastoma cell lines, varying
the ions LET. They found that U251MG RBE at 10% of survival ranges from 1.65 (LET
20 keV/µm) to 2.95 (LET 105 keV/µm), also in this case, despite the different LET, this
latter RBE value is compatible with the one we measured for the same cell line, but the
irradiation configurations are very different.
Combined treatment biological effectiveness
For the combination of irradiation and Epothilone B, C-ions effectiveness relative to
photons was calculated as the ratio between the slopes of the two exponential survival
curves (
αC
αX
). Also in this case, the ratio did not depend on the survival level and its
value resulted 2.7 ± 0.2 and 2.4 ± 0.1 for A549 and U251MG cells, respectively.
7.3 Radiation-drug interaction
The interaction mechanism between radiation and Epothilone B was investigated ap-
plying the model proposed by Luttjeboer et al, as described in Chapter 6, in order to
determine if they interact in an additive way or if the drug acts enhancing radiation ef-
fect (synergic interaction).
For each cell line and radiation (proton, carbon ion, photon beams), the additivity re-
gion delimited by the overlapping and independent additivity curves was represented
in the dose-survival plane. The independent additivity (IA) curve and the overlapping
one (OA) were built starting from the parameters of the dose-survival curves relative to
irradiation alone and combined to Epothilone B, as described in Chapter 6.
In this section the analysis performed for photon, proton and carbon ion irradiation for
each cell line will be presented.
7.3.1 Photon-drug interaction
In figures from 7.7 to 7.9 the graphs showing the analysis of the photon-Epothilone B
interaction for A549, U251MG and DAOY cells are displayed: the additivity region is
delimited by the dotted (independent additivity) and the dashed (overlapping additiv-
ity) lines. Experimental values of surviving fractions (full symbols) of cells irradiated
and treated with Epothilone B are represented and associated with error bars. The solid
line represents the fit to the experimental data according to equation 6.2.
In table 7.7 the parameters α, β, S0 and D? used to calculate the independent and over-
lapping additivity curves (equations 6.9 and 6.10) are reported. Details for this calcula-
tion are reported in Chapter 6. In the same table, the Dose Enhancement Factor values,
calculated according to equation 6.3 are reported.
The experimental data relative to the combined treatment (photon beams and Epothilone
B) are located below the additivity region for each cell line, indicating a synergic radiation-
drug interaction.
The area of the additivity region obtained for DAOY cells is smaller than that of the other
cell lines studied. This is due to the fact that the survival curve present a small shoulder
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with respect to A549 and U251MG cell curves.
Parameter A549 U251MG DAOY
Photon-drug interaction
α[Gy−1] 0.34 0.38 0.51
β[Gy−2] 0.028 0.028 0.022
S0 0.39 0.34 0.38
D?[Gy] 2.3 2.4 1.8
DEF10% 1.5 ± 0.1 1.6 ± 0.2 1.6 ± 0.2
Table 7.7: Parameters for the calculation of the independent and overlapping additivity curves for
the analysis of photon-drug interaction and Dose Enhancement Factor (DEF) values.
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Figure 7.7: Analysis of photon-drug interaction in A549 cells. Experimental data relative to photon
irradiation combined with 0.075 nM Epothilone B are reported and fitted with the solid line (CT).
The dotted line (IA) represents the independent additivity; the dashed line (OA) is relative to the
overlapping additivity.
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Figure 7.8: Analysis of photon-drug interaction in U251MG cells. Experimental data relative to
photon irradiation combined with 0.125 nM Epothilone B are reported and fitted with the solid line
(CT). The dotted line (IA) represents the independent additivity; the dashed line (OA) is relative
to the overlapping additivity.
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Figure 7.9: Analysis of photon-drug interaction in DAOY cells. Experimental data relative to
photon irradiation combined with 0.035 nM Epothilone B are reported and fitted with the solid line
(CT). The dotted line (IA) represents the independent additivity; the dashed line (OA) is relative
to the overlapping additivity.
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Parameter A549 U251MG DAOY
Proton-drug interaction
α[Gy−1] 0.56 0.54 0.57
β[Gy−2] 0.05 0.07 0.04
S0 0.36 0.38 0.37
D?[Gy] 1.6 1.5 1.6
DEF10% 1.2 ± 0.1 1.4 ± 0.1 1.3 ± 0.1
Table 7.8: Parameters for the calculation of the independent and overlapping additivity curves for
the analysis of proton-drug interaction and Dose Enhancement Factor (DEF) values.
7.3.2 proton-drug interaction
In figures from 7.10 to 7.12 the graphs showing the analysis of the proton-Epothilone B
interaction for A549, U251MG and DAOY cells are displayed: the additivity region is de-
limited by the dotted (independent additivity) and the dashed (overlapping additivity)
lines. Experimental values of surviving fractions (full symbols) of cells irradiated and
treated with Epothilone B are represented and associated with error bars. The solid line
represent the fit to the experimental data according to equation 6.2.
In table 7.8 the parameters α, β, S0 and D? used to calculate the independent and over-
lapping additivity curves (equations 6.9 and 6.10) are reported. Details for this calcula-
tion are reported in Chapter 6. In the same table, the Dose Enhancement Factor values,
calculated according to equation 6.3 are reported.
Also for proton beams, the experimental data relative to the combined treatment are lo-
cated below the additivity region for each cell line, indicating a synergic radiation-drug
interaction.
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Figure 7.10: Analysis of proton-drug interaction in A549 cells. Experimental data relative to proton
irradiation combined with 0.075 nM Epothilone B are reported and fitted with the solid line (CT).
The dotted line (IA) represents the independent additivity; the dashed line (OA) is relative to the
overlapping additivity.
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Figure 7.11: Analysis of proton-drug interaction in U251MG cells. Experimental data relative to
proton irradiation combined with 0.125 nM Epothilone B are reported and fitted with the solid line
(CT). The dotted line (IA) represents the independent additivity; the dashed line (OA) is relative
to the overlapping additivity.
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Figure 7.12: Analysis of proton-drug interaction in DAOY cells. Experimental data relative to
proton irradiation combined with 0.035 nM Epothilone B are reported and fitted with the solid line
(CT). The dotted line (IA) represents the independent additivity; the dashed line (OA) is relative
to the overlapping additivity.
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Parameter A549 U251MG
Carbon ion-drug interaction
α[Gy−1] 1.69 1.57
S0 0.43 0.44
D?[Gy] 0.49 0.53
DEF 1.13 ± 0.06 1.26 ± 0.05
Table 7.9: Parameters for the calculation of the independent and overlapping additivity curves for
the analysis of C-ion-drug interaction and Dose Enhancement Factor (DEF) values.
7.3.3 Carbon ion-drug interaction
In figure 7.13 and 7.14 the graphs showing the analysis of the carbon ion-Epothilone B in-
teraction for A549 and U251MG cells are displayed. In the case of carbon ion irradiation,
the dose-survival curves are purely exponential, thus the independent and overlapping
additivity curves (obtained shifting downwards and to the left the survival curve rela-
tive to irradiation alone as previously described) coincides: the independent and over-
lapping additivity curves are represented with the dotted line. Experimental values of
surviving fractions (full symbols) of cells irradiated and treated with Epothilone B are
represented and associated with error bars. The solid line represent the fit to the experi-
mental data according to equation 6.2.
In table 7.9 the parameters α, S0 and D? used to calculate the independent and over-
lapping additivity curves (equations 6.9 and 6.10 where the β parameter was set to 0)
are reported. Details for this calculation are reported in Chapter 6. In the same table,
the Dose Enhancement Factor values, calculated according to equation 6.3 are reported.
Since the curves are purely exponential, the DEF value does not depend on the survival
level, but can be simply evaluated as the ratio between the slopes of the curves relative
to irradiation alone or in combination with Epothilone B.
Experimental data relative to the combined treatment for A549 cells are very close to the
curve of additivity, indicating a purely additive radiation-drug interaction. Data relative
to U251MG show two different behaviors: at the lower doses they are very close (or even
over) to the additivity curve, but at the higher doses they deviate, indicating a slightly
more than additive interaction. Since only three independent experiments have been
performed with carbon ion beams, it is desirable to perform other experiments with car-
bon ions to consolidate the obtained results.
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Figure 7.13: Analysis of C-ion-drug interaction in A549 cells. Experimental data relative to C-ion
irradiation combined to 0.075 nM Epothilone B are reported and fitted with the solid line (CT).
The dotted line (IA) represents the independent additivity; the dashed line (OA) is relative to the
overlapping additivity.
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Figure 7.14: Analysis of C-ion-drug interaction in U251MG cells. Experimental data relative to
C-ion irradiation combined to 0.125 nM Epothilone B are reported and fitted with the solid line
(CT). The dotted line (IA) represents the independent additivity; the dashed line (OA) is relative
to the overlapping additivity.
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7.3.4 Result interpretation
As shown in the previous figures, experimental data relative to the combined treatment
of low-LET radiations (photons and protons) and Epothilone B fall below the additivity
region, indicating a slightly synergic interaction between radiation and drug. Thus, with
photon and proton beams Epothilone B act as a radiosensitizing agent in all the cell lines
analyzed, enhancing the cell radiation sensitivity.
Our results relative to the irradiation of A549 cells with photon beams are in agreement
with those of Baumgart et al. (2012a), who found for the same cell line a synergic effect
of Epothilone B combined to photon beams. Roher-Bley et al. (Roher Bley et al., 2013,
2009) found an at least additive effect for the combination of Epothilone B with X-rays
irradiation on A549 cells. (Oehler et al., 2011) observed that Epothilone B is effective
against different medulloblastoma cell lines and that at picomolar concentrations and
combined with X-rays it reduces cell clonogenic survival. Hofstetter et al. (2005) found
that Epothilone B combined with X-rays has a radiosenziting effect in human colon ade-
nocarcinoma cells (SW480) and in p53-null MEF cells.
To our knowledge no data are published on the combination of Epothilone B with proton
irradiation.
Interestingly the radiosensitizing effect we observed, occur at concentrations that did
not cause a G2/M block. Thus, the radiosensitizing effect of Epothilone B is not neces-
sarily only related to a G2-M arrest, but other mechanisms occurring at sub-nanomolar
concentrations can be involved in radiosensitization and might be studied. As reported
in Chapter 4, Hofstetter et al. (2005) found that the supra-additive effect of the combi-
nation of Epothilone B with irradiation occurs at concentrations not leading to a G2/M
cell accumulation (as in our case) and they conjecture that the radiosensitization can
be due to an S-phase related mechanism, stating that some microtubule-associated pro-
teins have been discovered modulating cell stress response after irradiation also in other
phases of the cell cycle, such as the S one.
Looking at the previously reported graphs, the reader can observe that the synergism
results weaker for proton than for photon beams, especially in A549 cells. Also the DEF
values resulted to be smaller for proton beams when compared to the correspondent
photon values.
We conjecture that the differences in correctly-reparable damages induced by photon
or proton irradiation may explain the weaker synergism found for protons. Indeed, as
mentioned in Chapter 3, it was shown that Epothilone B reduces DNA repair of cancer
cells and this property may be less relevant in the case of drug interaction with radiation
inducing more complex and less reparable lesions.
Moreover the fact that after DSBs induced by photons or protons, different repair path-
ways can be followed (i.e. Homologous Recombination and Non Homologous End Join-
ing, as discussed in the previous section) might explain the different action of Epothilone
B on cells irradiated with photon or proton beams. For this reason, it can be interesting
to study the DNA repair mechanism after Epothilone B exposure and proton irradiation,
to well understand the differences in the Epothilone B-radiation interaction found with
photons and protons.
The previous considerations are confirmed by the fact that with high-LET radiation
(i.e. carbon ions) the radiation enhancement caused by Epothilone B resulted weaker and
the radiation-drug interaction resulted to be simply additive in A549 cells and slightly
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more than additive in U251MG cells. Indeed, as discussed in the previous section, sur-
vival curves of high-LET irradiation lack the shoulder that is correlated to the repair
capacity. Thus, the DNA repair inhibition caused by Epothilone B might be negligible
when it is combined to carbon ions.
This behavior is typical of carbon ion irradiation when combined with chemotherapy
drugs. By way of example, Schlaich et al. (2013) found that independent cytotoxicities
occur when different chemotherapy drugs are combined with C-ion irradiation. Combs
et al. (2009) reported that the combination of TMZ and irradiation showed an additive
effect in glioblastoma cell lines (LN229 and U87MG).
Despite the weaker synergism with respect to photons, proton beams are very promis-
ing to be combined with a non tumor-specific drug (such as Epothilone B), due to their
good conformability to the tumor volume. Carbon ion irradiation resulted significantly
more effective than photon irradiation and the addition of Epothilone B even to high-
LET radiation may lead to better results in different tumors.
7.4 Cell invasion rate
Cell invasion rate relative to the control sample (not irradiated and not exposed to Epothilone
B) was measured for A549 and U251MG cells irradiated with photons and carbon ions,
with or without Epothilone B at the same concentration used for survival assays (0.075
and 0.125 nM, respectively).
Obtained results are reported for both the cell lines in the next paragraphs.
7.4.1 A549 cells
In figure 7.15 the relative invasion index of A549 cells exposed to photons (at doses of
1.5 and 3 Gy)and carbon ions (at doses of 0.75 and 1.5 Gy) treated or not with 0.075 nM
Epothilone B is displayed. Reported data are the mean of two independent experiments.
Data collected in each experiment are reported in Appendix C.
In table 7.10 the relative invasion index values and the error bars (calculated as described
in Chapter 6) are reported.
Reported results show that the use of Epothilone B significantly reduces the basal in-
vasion rate. Photon irradiation alone at these doses seems not to have effects on cells
invasive capacity; conversely carbon ion irradiation alone reduces the invasion rate.
Obtained results will be discussed in Section 7.4.3.
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Figure 7.15: Invasion Index relative to the control sample of A549 cells irradiated with photons or
carbon ions combined with 0.075 nM Epothilone B.
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Dose [Gy] Relative I.I. [%] error [%]
Photon beams
0 100 10
1.5 93.7 9.4
3 86.0 8.6
Photon beams + Epothilone B
0 61.7 6.2
1.5 54.9 5.5
3 44.5 4.4
C-ion beams
0 100 10
0.75 84.5 8.5
1.5 49.3 4.9
C-ion beams + Epothilone B
0 55.8 5.6
0.75 40.7 4.1
1.5 33.9 3.4
Table 7.10: Invasion Index relative to the control sample of A549 cells irradiated with photons and
carbon ions combined with 0.075 nM Epothilone B.
7.4.2 U251MG cells
Dose [Gy] Relative I.I. [%] error [%]
Photon beams
0 100 10
1.5 91.2 12.8
3 88.6 11.9
Photon beams + Epothilone B
0 65.9 6.6
1.5 57.9 5.8
3 49.1 4.9
C-ion beams
0 100 10
0.75 71.1 7.1
1.5 60.0 6.0
C-ion beams + Epothilone B
0 63.7 6.4
0.75 53.4 6.6
1.5 40.5 4.0
Table 7.11: Invasion Index relative to the control sample of U251MG cells irradiated with photons
and carbon ions combined with 0.125 nM Epothilone B.
In figure 7.16, the relative invasion index of U251MG cells exposed to photons (at
doses of 1.5 and 3 Gy, mean of two independent experiments)and carbon ions (at doses
of 0.75 and 1.5 Gy, mean of three independent experiments) treated or not with 0.125 nM
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Epothilone B is reported. Data collected in each experiment are reported in Appendix C.
In table 7.11 the relative invasion index values and the error bars (calculated as described
in Chapter 6) are reported.
Reported results show that also for this cell line the use of Epothilone B significantly
reduces the basal invasion rate. Also in this cell line photon irradiation at these doses
seems not to have effects on cells invasive capacity; conversely carbon ion irradiation
alone reduces the invasion rate. Obtained results will be discussed in Section 7.4.3.
Figure 7.16: Invasion Index relative to the control sample of U251MG cells irradiated with photons
or carbon ions combined with 0.125 nM Epothilone B.
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7.4.3 Result interpretation
The obtained results show that for both the cell lines the use of Epothilone B reduces the
invasion rate, as described in Chapter 4.
An invasion rate reduction was observed also in cells irradiated with carbon ions and
not treated with the drug, suggesting that high-LET irradiation may reduce cancer inva-
sive capacity.
This effect was not observed in cells simply irradiated with photon beams: despite an
invasion reduction at 3 Gy of X-rays was observed in both cell lines, it is not statistically
significative.
In literature there are some studies that show that carbon ion irradiation inhibits cell in-
vasion: by way of example, Akino et al. (2009) found that carbon ion irradiation reduces
migration and invasion in NSC lung cancer cells (among wich the A549 line, used in
the present study); Fujita et al. (2015) reported that carbon ions suppress migration and
invasion in human pancreatic carcinoma cells.
Our results suggest that the combination of Epothilone B and carbon ion irradiation
can lead to advantages even in the suppression of cancer cell metastatic potential.
7.5 Cell growth
U251MG cell growth after carbon ion irradiation combined or not with Epothilone B was
investigated according to the procedure described in Chapter 6.
In figures 7.17 the ratio between the number of cells at time t (n(t)) and the number of
cells initially plated (n0) is reported as a function of time (mean of two independent ex-
periments, data are reported in table 7.13) for cell simply irradiated (a) and irradiated
and treated with 0.125 nM Epothilone B.
The results of the single experiments are reported in Appendix C.
Data were fitted according to equations 4.1 and 6.12, for the control and the treated sam-
ples respectively. The fit parameters are reported in table 7.13.
We can observe that, despite the great uncertainties due to the fact that there are few
experimental points, C-ion irradiation induces a significant delay in cell growth and that
this delay is enhanced when radiation is combined with Epothilone B. After this delay,
cell growth re-start with a slope that is very similar to the control sample one.
The observed growth delay can be due to the fact that damage signaling and attempts
to repair need more time, due to the complexity of the damages induced by high-LET
irradiation alone. Moreover, as previously said, when irradiation is combined with the
chemotherapy drug, DNA repair is partially inhibited, so that growth delay is enhanced.
It can be interesting to compare these results with a cell-cycle analysis of samples irra-
diated with carbon ions and treated or not with Epothilone B, in order to better under-
stand the effects we found on cell growth. For this reason a cytofluorimetric analysis of
samples irradiated with carbon ions (pretreated or not with Epothilone B) is planned.
Moreover similar experiments on cell growth with photon beams are planned in order
to make a comparison with the results obtained with carbon ion irradiation. As a matter
of fact, high-LET irradiation effects on cell growth have been widely debated in the past
and light ion irradiation seems to be more effective in inducing cell growth delay with
respect to conventional radiotherapy.
98 7.5 Cell growth
Figure 7.17: Cell growth of U251MG cells simply irradiated (a) or pretreated with 0.125 nM
Epothilone B (b)
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U251MG
Irradiation Irradiation + Epothilone B (0.075 nM)
time [hours]
n(t)
n0
error time [hours]
n(t)
n0
error
control sample
26.00 1.87 0.19 25.50 1.27 0.13
49.50 2.96 0.56 48.67 1.89 0.19
73.46 6.29 0.63 72.66 3.76 0.44
96.88 11.00 1.43 96.09 6.25 0.62
0.75 Gy
26.00 1.36 0.15 25.50 0.98 0.10
49.50 1.90 0.19 48.67 1.45 0.15
73.46 4.28 0.43 72.66 3.29 0.64
96.88 7.95 0.80 96.09 5.24 0.52
1.5 Gy
26.00 1.23 0.18 25.50 0.84 0.08
49.50 1.64 0.16 48.67 1.23 0.12
73.46 3.50 0.41 72.66 2.38 0.22
96.88 6.98 0.70 96.09 3.66 0.79
Table 7.12: U251MG cell growth data: ratio between the number of cell at time t (n(t)) and cells
initially seeded n0. Error bars are the maximum value between the standard error and the 10% of
the ratio. Reported data are the mean of two independent experiments.
U251MG
Irradiation Irradiation + Epothilone B (0.075 nM)
control sample
tD 28.1 ± 1.1 tD 29.9 ± 2.6
x 17.6 ± 4.2
0.75 Gy
tD 26.1 ± 2.1 tD 28.2 ± 2.3
x 20.2 ± 3.9 x 29.5 ± 3.3
1.5 Gy
tD 25.3 ± 2.3 tD 31.8 ± 4.3
x 27.6 ± 4.0 x 35.5 ±3.4
Table 7.13: U251MG cell growth fit parameters.

Conclusions and outlook
Recently, the use of charged hadron beams in oncological treatments is rapidly growing
and new cancer therapy modalities are being studied with the aim of achieving better
tumor local control and reducing the metastasis probability.
In particular, treatments that combine the use of radiation and chemotherapy attracted
a lot of interest due to the possibility of combining a very local therapy (i.e. radiother-
apy) to a systemic one (i.e. chemotherapy) and to the challenge of exploiting eventual
radiosensitizing effects of the chemotherapy drug.
In this work the interaction of charged hadron (carbon ion and proton) Spread-Out-
Bragg-peak beams used in oncological treatments combined with the the microtubule-
stabilizing agent Epothilone B was investigated and compared with the interaction of
LINAC photon beams with this drug.
Epothilone B is known to stop cells in the G2/M phase, the more radiosensitive of cell
cycle, and to inhibit DNA repair mechanism, for this reason it is promising to be used as
radiosensitizer.
The study was performed in vitro on three human cancer cell lines: A549 (non small
cell lung adenocarcinoma), U251MG (glioblastoma multiforme) and DAOY (pediatric
medulloblastoma).
Despite in literature there are different study on the combination of Epothilone B with
photon beam irradiation, to our knowledge no data are published on its interaction with
charged hadrons.
The experiments described in this thesis were performed with proton and carbon
ion beams at CNAO (Pavia) or with photon beams at the Fondazione IRCCS - Istituto
Nazionale dei Tumori (Milano). Cell clonogenic survival, invasion rate and growth were
studied after irradiation and treatment with Epothilone B at sub-nanomolar concentra-
tions.
For all the three cell lines, survival curves after photon and proton irradiation alone
showed a linear quadratic behavior with a proton RBE at 10% survival, equal to 1.5 ±
0.2 for A549 and U251MG cells and to 1.2 ± 0.1 for DAOY cells. Differently, the survival
curves for the combined treatment Epothilone B - radiation showed a linear trend and
the analysis of the interaction of Epothilone B with photons or protons, performed ac-
cording to the method proposed by Luttjeboer et al. (2010), indicated a synergism. This
result suggests that Epothilone B at sub-nanomolar concentration can act as a radiosen-
sitizer on this cancer cell lines. The synergism in radiation-drug interaction resulted
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weaker for protons than for photons; this difference is probably due to different amount
of correctly-reparable damages induced by photons and protons, as discussed in the pre-
vious Chapter.
Due to the high radiosensitivity of the pediatric medulloblastoma (DAOY) cells, the com-
bination of carbon ions and Epothilone B was studied only for A549 and U251MG cells.
As typical of curve obtained after high-LET irradiation, dose-survival curves after car-
bon ion irradiation alone showed a linear trend, without any shoulder in both these cell
lines. The same behavior was found on cells irradiated and treated with Epothilone B.
The analysis of the radiation-drug mechanism showed a simply additive interaction in
A549 cells and a slightly supra-additive interaction in U251MG cells. A549 and U251MG
RBE at 10% of survival resulted equal to 3.5 ± 0.3 and 3.1 ± 0.3, respectively.
The cytofluorimetric analysis performed on cells treated with Epothilone B at dif-
ferent sub-nanomolar concentrations do not show an accumulation in the G2/M phase,
reported in literature at higher concentrations. Despite this fact, in the present study a
radiosensitizing effect was found at low concentrations, when the drug is combined with
low-LET irradiation. This results are in agreement with results reported in literature on
the combined use of Epothilone B and photon irradiation, as discussed in the previous
Chapter.
Furthermore, Epothilone B alone or combined with photon and carbon ion irradia-
tion resulted to inhibit A549 and U251MG cell invasive capacity (experiments on DAOY
cells not performed). A reduction of the invasion rate was found even on cells simply
irradiated with carbon ions, suggesting that high-LET irradiation can reduce cancer cell
metastatic potential. This effect was not observed in cells simply irradiated with photon
beams.
Carbon ion irradiation alone resulted to induce a growth delay in U251MG cells and
this effect is enhanced when irradiation is combined with Epothilone B.
We can conclude that Epothilone B acts as a radiosensitizing agent on the three cell
lines studied and that the interaction resulted synergic with low-LET radiations (pho-
tons and protons) and additive (or slightly supra-additive, in the case of U251MG cells)
with carbon ions. For this reason it is promising to be used even in combination with
charged hadrons. Moreover it induces a growth delay and it reduces the invasion ca-
pacity, especially when combined to carbon ion irradiation, suggesting that the combi-
nation of Epothilone B and carbon ions can lead to advantages even in reducing cancer
cell metastatic potential.
In order to better understand the interaction between radiation and Epothilone B,
other studies will be performed. In particular cell cycle analysis of irradiated cells pre-
treated or not with Epothilone B are planned in order to study more in detail the effect
of the combination of Epothilone B and radiation on cycle progression.
Moreover experiments on cell growth after photon irradiation (combined or not with
Epothilone B) are programmed, in order to compare this results with those obtained
with carbon ions.
Since in literature there are some evidence that high-LET radiation inhibit cancer cell in-
vasive capacity (as commented in Chapter 7), in this Thesis we gave the priority to the
study of cell invasion after carbon ion irradiation and to the comparison of the results
with those obtained with photon beams, considered to be the reference radiation. In the
next future it can be desirable to perform analogue study on cell invasion even after pro-
ton irradiation (combined or not with Epothilone B).
Results published in this thesis and the ones that will be reported in the next pub-
lications provide a radiobiological basis for further experiments on the combination of
charged hadrons and Epothilone B, as well as for clinical studies.
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APPENDIX A
Fit details
In this Appendix a schematic description of the fit performed with the software Origin-
Lab (version: OriginPro 7.5) will be given.
Curves fitting was performed exploiting the method of least squares. In particular, for
survival curves the software minimizes the chi-square function:
χ2 =
n∑
i=1
(
yexp,i − ycalc,i(xi, α, β)
σi
)2
(A.0.1)
where n is the number of experimental points, yexp,i are the measured y values at xi and
ycalc,i are the correspondent calculated values.
In order to find the parameters that minimize this function, the software applies the
Levenberg-Marquardt algorithm, a numeric minimization algorithm. A very schematic
description of this algorithm is given in the following lines.
This iterative procedure consists of different steps:
1. Once the initial parameter vector b is set, the software solves the Levenberg-Marquardt
equation A.0.2 for δ, in order to correct the initial b values:
(JTJ + λI)δ = JT r (A.0.2)
where r is the residual vector, whose components are:
ri = yexp,i − ycalc,i
λ is the damping parameter, chosen by the software as a balance between a step
and the following one and J is the jacobian matrix of derivatives of the residuals
with respect to the parameters.
2. Once δ is found, χ2(b+ δb) is evaluated. If χ2(b+ δb) ≥ χ2(b), the step is rejected, λ
is incremented and the software goes back to point 1. Otherwise, the b values and
the residual vector are updated to the new ones (bnew = b + δb), λ is reduced and
the software goes back to step 1 with the new parameter vector bnew and the new
residuals.
3. The procedure iterates and stops when the χ2values computed in two successive
iterations are small enough, compared with the tolerance (the fit converges).
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Tolerance = |χ
′2 − χ2
χ′2 + χ2
|
where χ′2 is the chi-square of the last iteration and χ2 is the chi-square of the cur-
rent iteration.
In weighted fits the function to be minimized becomes
χ2 =
n∑
i=1
wi
(
yexp,i − ycalc,i(xi, α, β
σi
)2
(A.0.3)
where wi are the weights.
Survival curve fitting
For the fit of dose-survival curves according to the LQ model (S = S0exp(−αD− βD2)),
a weighted fit was performed, minimizing the function A.0.3, that in this case is given
by:
χ2 =
∑n
i=1 wi
(
Sexp,i − Scalc,i(Di, α, β
σi
)2
where n is the number of experimental points, Sexp,i are the measured surviving frac-
tions at dose Di and Scalc,i are the correspondent calculated values.
Error bars were used as weights: wi =
1
σ2i
.
Growth curve fitting
Growth curves (cell number relative to the initial number of seeded cells vs. time) were
fitted performing a weighted fit according to equation:
n(t)
n0
= 2
t
TD
for cells not irradiated and not treated with Epothilone B; or
n(t)
n0
= 2
t− x
TD
for treated samples, as described in Chapter 6. n(t) is the cell number at time t, n0 is the
number of cells initially plated, TD is the doubling time and x the delay induced by cell
treatment/irradiation.
In this case, the function to be minimized is:
χ2 =
∑n
i=1 wi

(
n(t)
n0
)
−
(
n(t)
n0
)
(ti, x, TD)
σi

2
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where n is the number of experimental points,
n(t)
n0 exp,i
are the measured ratios between
the cell number at time ti and the number of cell initially seeded and (
n(t)
n0
)(ti, x, TD) are
the correspondent calculated values.
Error bars were used as weights: wi =
1
σ2i
.

APPENDIX B
Flow cytometry
Flow cytometry is a technique widely used in biotechnology and employed in cell count-
ing, cell sorting and so on.
Flow cytometers analyze thousands particles per second in real time. The basic structure
of a flow cytometer is made up of five components:
1 Fluidic system: a sheath fluid that carries and aligns cells into a stream of single
particles.
2 Optical system made up of lasers. The cells passes through the optical system:
light scattering or fluorescence emission (if cells are labeled with fluorochromes)
provides information about cell properties.
3 Detectors and analogue-to-digital converters.
4 Amplification system.
5 Computer to analyze signals.
In the next paragraphs this five components will be briefly described, basing on the
guide by Raman et al. (2014).
Fluidic system. The fluidic system is made up of a central channel in which the sample
is injected; this channel is enclosed by an outer sheath that contains a faster flowing fluid
that creates a massive drag effect on central chamber, altering the velocity of the central
fluid.
The fluid flow front becomes parabolic with greatest velocity at its center, creating a sin-
gle stream of particles (hydrodynamic focusing).
This focusing permits to collect and analyze single particle signals.
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Optical system and detectors.
Light scattering. When single particles passes through the optical system, they are
hit by light that is scattered in different directions.
Light scattered in the forward direction, is collected by a lens (forward scatter channel,
FSC). The FSC intensity is related to the particle size and moreover it can be used to dis-
tinguish between cellular debris and living cells.
Light measured at about 90o angle to the excitation line is collected by the side scatter
channel (SSC) and gives information on the granular content within a particle.
Fluorescence measurements. When cells are labeled with fluorescent probes (as in
our case for the measurements of cell cycle) and they are hit by laser light at oppor-
tune wavelengths, they emit fluorescence light whose intensity typically has a peak at
a wavelenght different from the absorbed light one (Stokes shift). Flow cytometers use
separate fluorescence (FL) channels to detect light emitted. The specificity of detection
is controlled by optical filters. Typically photomultiplier tubes (PMTs) and silicon pho-
todiodes are used as detectors.
Signal amplification and processing. The signal is amplified with PMT, converted
with an analogue-to-digital converter and sent to the computer. Signals are collected
and processed for each detectors (FSC and SSC, as well as for fluorescence detectors FL):
signal area, height and width are recorded. By way of example, for the analysis of cycle
with Propidium Iodide, whose emission spectrum is in the red region and has a peak
correspondent to 610 nm, fluorescence signals recorded in the fluorescence channel cor-
respondent to the emission region of Propidium Iodide are processed: the signal area is
proportional to the fluorescence emission intensity so that fluorescence histograms are
built and analyzed, as described in Chapter 4.
In order to select the cell population to be analyzed or to distinguish debris from liv-
ing cells, different gates can be applied. For example, gates can be applied according to
physical characteristics. For instance, debris and aggregates can be distinguished from
single cells by size, that can be evaluated by forward scatter: a gate can be applied se-
lecting an opportune region in the plane SSC vs FSC. Moreover, in order to eliminate
doublets in fluorescence histograms, a gate can be applied in the plane signal height vs.
signal area, as shown in Chapter 4.
In the present study, flow cytometry was exploited for cell cycle analysis in cell
treated with Epothilone B at different concentrations, but lots of different cell character-
istics can be analyzed with this technique, such as study of ploidy and cell proliferation,
immunophenotypic analysis, analysis of apoptosis and so on. A schematic view of the
flow cytometer setup is displayed in figure A.0.
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Figure A.0: Schematic view of the flow cytometer setup (Raman et al., 2014)
.

APPENDIX C
Single experiment results
In Chapter 7 the presented results are the mean of different experiments (at least 3 for
survival curves and at least 2 for Invasion rate and growth curves). In this Appendix the
results obtained in each experiment will be reported.
C.1 Dose-survival curves
In this section the results of the clonogenic survival assays described in Chapter 6 will be
reported for each irradiation condition (photon, proton or carbon ion beams combined
or not with the use of Epothilone B) and cell line.
C.1.1 Photon irradiation
In table C.1, C.2 and C.3 the surviving fractions (S) obtained through the clonogenic
survival assays performed on cells irradiated with photon beams are reported, as well
as the mean values (S) and the error bars (obtained as explained in Chapter 6).
C.1.2 Proton irradiation
In table C.4, C.5 and C.6 the surviving fractions (S) measured in each experiment through
clonogenic survival assays, the mean surviving fractions (S) and error bars are reported
for cells irradiated with protons.
C.1.3 Carbon ion irradiation
In table C.7 and C.8 the surviving fractions (S) of the clonogenic survival assays per-
formed on A549 and U251MG cells irradiated with proton beams are reported, as well
as the mean values (S) and the error bars (obtained as explained in Chapter 6).
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A549 cells
Photons
Dose [Gy] S1 S2 S3 S4 S5 S error
0 1 1 1 1 1 1 0.1
0.5 0.83 0.83 0.83 0.86 0.86 0.84 0.08
1 0.68 0.68 0.65 0.61 0.66 0.66 0.07
2 0.48 0.49 0.50 0.50 0.50 0.49 0.05
3 0.26 0.28 0.28 0.21 0.23 0.25 0.03
5 0.098 0.106 0.113 0.09 0.087 0.10 0.01
7 0.023 0.022 0.024 0.020 0.023 0.022 0.002
Photons + Epothilone B
0 0.41 0.41 0.41 0.41 0.40 0.41 0.04
0.5 0.30 0.30 0.31 0.28 0.32 0.30 0.03
1 0.19 0.21 0.21 0.15 0.20 0.19 0.02
2 0.087 0.097 0.115 0.073 0.083 0.091 0.009
3 0.038 0.047 0.054 0.031 0.039 0.042 0.004
5 0.014 0.015 0.015 0.011 0.014 0.014 0.001
Table C.1: Surviving fractions (S) of A549 cells photon-irradiated and pretreated or not with 0.075
nM Epothilone B. The mean surviving fraction (S) and error bars are also reported.
U251MG cells
Photons
Dose [Gy] S1 S2 S3 S4 S error
0 1.00 1.00 1.00 1.00 1.00 0.10
0.5 0.85 0.86 0.84 1.04 0.90 0.09
1 0.74 0.74 0.77 0.66 0.72 0.07
2 0.54 0.54 0.47 0.38 0.48 0.05
3 0.26 0.26 0.18 0.19 0.22 0.02
5 0.11 0.10 0.05 0.04 0.07 0.02
7 0.026 0.025 0.012 0.015 0.019 0.004
Photons + Epothilone B
0 0.39 0.42 0.42 0.41 0.04
0.5 0.21 0.26 0.25 0.24 0.02
1 0.11 0.14 0.13 0.13 0.01
2 0.05 0.07 0.07 0.06 0.01
3 0.025 0.030 0.033 0.029 0.003
5 0.010 0.006 0.006 0.007 0.001
Table C.2: Surviving fractions (S) of U251MG cells photon-irradiated and pretreated or not with
0.125 nM Epothilone B. The mean surviving fraction (S) and error bars are also reported.
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DAOY cells
Photons
Dose [Gy] S1 S2 S3 S error
0 1.00 1.00 1.00 1.00 0.10
0.5 0.89 0.85 0.75 0.83 0.08
1 0.69 0.71 0.70 0.70 0.07
2 0.38 0.38 0.34 0.37 0.04
3 0.17 0.18 0.17 0.17 0.02
5 0.039 0.041 0.044 0.041 0.004
7 0.010 0.010 0.011 0.010 0.001
Photons + Epothilone B
0 0.45 0.40 0.40 0.42 0.042
0.5 0.31 0.25 0.25 0.27 0.027
1 0.14 0.13 0.13 0.13 0.013
2 0.05 0.05 0.06 0.05 0.005
3 0.03 0.02 0.03 0.02 0.002
5 0.003 0.003 0.009 0.005 0.002
Table C.3: Surviving fractions (S) of DAOY cells photon-irradiated and pretreated or not with
0.035 nM Epothilone B. The mean surviving fraction (S) and error bars are also reported.
A549 cells
Protons
Dose [Gy] S1 S2 S3 S4 S error
0 1.0 1.0 1.0 1.0 1.0 0.1
0.5 1.0 0.8 0.8 0.8 0.9 0.1
1 0.6 0.5 0.5 0.5 0.6 0.1
2 0.2 0.3 0.2 0.2 0.2 0.0
3 0.16 0.12 0.10 0.12 0.13 0.01
4 / 0.045 0.049 0.051 0.048 0.005
5 0.07 0.02 0.02 0.01 0.03 0.01
Protons + Epothilone B
0 0.38 0.39 0.40 0.39 0.04
0.5 0.27 0.26 0.25 0.26 0.03
1 0.12 0.13 0.12 0.12 0.01
2 / 0.06 0.06 0.06 0.01
3 0.017 0.028 0.024 0.023 0.003
4 / 0.013 0.010 0.012 0.002
Table C.4: Surviving fractions (S) of A549 cells proton-irradiated and pretreated or not with 0.075
nM Epothilone B. The mean surviving fraction (S) and error bars are also reported.
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U251MG cells
Protons
Dose [Gy] S1 S2 S3 S4 S error
0 1.00 1.00 1.00 1.00 1.00 0.10
0.5 0.85 0.86 0.84 1.04 0.90 0.09
1 0.74 0.74 0.77 0.66 0.72 0.07
2 0.54 0.54 0.47 0.38 0.48 0.05
3 0.26 0.26 0.18 0.19 0.22 0.02
5 0.11 0.10 0.05 0.04 0.07 0.02
7 0.026 0.025 0.012 0.015 0.019 0.004
Protons + Epothilone B
0 0.42 0.39 0.41 0.42 0.41 0.04
0.5 0.15 0.25 0.25 0.26 0.23 0.03
1 0.06 0.14 0.14 0.13 0.11 0.02
2 0.031 0.046 0.046 0.050 0.043 0.004
3 0.012 0.017 0.017 0.013 0.015 0.001
4 0.006 0.006 0.006 0.006 0.006 0.001
Table C.5: Surviving fractions (S) of U251MG cells proton-irradiated and pretreated or not with
0.125 nM Epothilone B. The mean surviving fraction (S) and error bars are also reported.
DAOY cells
Protons
Dose [Gy] S1 S2 S3 S4 S error
0 1.00 1.00 1.00 1.00 1.00 0.10
0.5 0.70 0.81 0.82 0.88 0.80 0.08
1 0.38 0.60 0.61 0.61 0.55 0.06
2 0.18 0.28 0.28 0.30 0.26 0.03
3 0.11 0.13 0.13 0.14 0.13 0.01
4 0.06 0.06 0.05 0.06 0.06 0.01
5 0.025 0.026 0.020 0.018 0.022 0.002
Protons + Epothilone B
0 0.31 0.43 0.41 0.41 0.39 0.04
0.5 0.23 0.29 0.27 0.29 0.27 0.03
1 0.123 0.143 0.122 0.123 0.128 0.015
2 0.065 0.067 0.057 0.059 0.062 0.006
3 0.031 0.025 0.023 0.020 0.025 0.002
4 0.015 0.012 0.011 / 0.013 0.003
Table C.6: Surviving fractions (S) of DAOY cells proton-irradiated and pretreated or not with 0.035
nM Epothilone B. The mean surviving fraction (S) and error bars are also reported.
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A549 cells
C-ions
Dose [Gy] S1 S2 S3 S error
0 1.00 1.00 1.00 1.00 0.10
0.5 0.54 0.55 0.62 0.57 0.06
0.75 0.25 0.26 0.40 0.30 0.05
1 0.12 0.13 0.19 0.15 0.02
1.5 0.065 0.066 0.083 0.071 0.007
2 0.029 0.030 0.034 0.031 0.003
3 0.009 0.009 0.013 0.010 0.001
C-ions + Epothilone B
0 0.41 0.39 0.41 0.40 0.04
0.5 0.19 0.19 0.21 0.20 0.02
0.75 0.09 0.09 0.13 0.10 0.01
1 0.04 0.04 0.08 0.06 0.01
1.5 0.018 0.020 0.042 0.026 0.008
2 0.007 0.007 0.013 0.009 0.002
Table C.7: Surviving fractions (S) of A549 cells carbon ion-irradiated and pretreated or not with
0.075 nM Epothilone B. The mean surviving fraction (S) and error bars are also reported.
U251MG cells
C-ions
Dose [Gy] S1 S2 S3 S error
0 1.00 1.00 1.00 1.00 0.10
0.5 0.75 0.56 0.52 0.61 0.07
0.75 0.41 0.31 0.33 0.35 0.04
1 0.21 0.16 0.16 0.17 0.02
1.5 0.12 0.08 0.07 0.09 0.01
2 0.049 0.036 0.036 0.041 0.004
3 0.014 0.012 0.009 0.012 0.002
C-ions + Epothilone B
0 0.45 0.42 0.38 0.42 0.04
0.5 0.31 0.20 0.20 0.24 0.04
0.75 0.17 0.11 0.09 0.13 0.02
1 0.064 0.046 0.040 0.050 0.007
1.5 0.028 0.021 0.019 0.023 0.003
2 0.009 0.008 0.008 0.008 0.001
Table C.8: Surviving fractions (S) of U251MG cells carbon ion-irradiated and pretreated or not
with 0.125 nM Epothilone B. The mean surviving fraction (S) and error bars are also reported.
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C.2 Cell-invasion rate
In this section the result of the invasion assays described in Chapter 6 will be reported
for each irradiation condition studied (photon or carbon ion beams combined or not to
the use of Epothilone B) and cell line (A549 and U251MG cells).
In table the invasion index relative to the control sample (I.I.r.) measured in each exper-
iment as well as the mean invasion rates and the error bars are reported for A549 and
U251MG cells irradiated with photons or carbon ions.
A549 cells
photons
Dose [Gy] I.I.r1 I.I.r.2 I.I.r. error
0 1.00 1.00 1.00 0.10
1.5 0.97 1.07 1.02 0.10
3 0.86 0.76 0.81 0.08
photons + Epothilone B
0 0.56 0.64 0.60 0.06
1.5 0.53 0.55 0.54 0.05
3 0.45 0.28 0.36 0.08
Table C.9: Relative invasion index of A549 cells irradiated with photon beams, pretreated or not
with 0.075 nM Epothilone B. The mean invasion index (S) and error bars are also reported.
U251MG cells
photons
Dose [Gy] I.I.r1 I.I.r.2 I.I.r. error
0 1.00 1.00 1.00 0.10
1.5 0.97 1.07 1.02 0.10
3 0.86 0.76 0.81 0.08
photons + Epothilone B
0 1.00 1.00 1.00 0.10
1.5 1.04 0.78 0.91 0.13
3 1.01 0.77 0.89 0.12
Table C.10: Relative invasion index of U251MG cells irradiated with photon beams, pretreated or
not with 0.125 nM Epothilone B. The mean invasion index (S) and error bars are also reported.
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A549 cells
C-ions
Dose [Gy] I.I.r1 I.I.r.2 I.I.r. error
0 1.00 1.00 1.00 0.10
0.75 0.86 0.83 0.85 0.08
1.5 0.47 0.52 0.49 0.05
photons + Epothilone B
0 0.56 0.56 0.56 0.06
0.75 0.39 0.42 0.41 0.04
1.5 0.33 0.35 0.34 0.03
Table C.11: Relative invasion index of A549 cells irradiated with carbon ion beams, pretreated or
not with 0.075 nM Epothilone B. The mean invasion index (S) and error bars are also reported.
U251MG cells
C-ions
Dose [Gy] I.I.r1 I.I.r.2 I.I.r.3 I.I.r. error
0 1.00 1.00 1.00 1.00 0.10
0.75 0.80 0.64 0.70 0.71 0.07
1.5 0.60 0.59 0.61 0.60 0.06
photons + Epothilone B
0 0.67 0.61 0.63 0.64 0.06
0.75 0.67 0.46 0.48 0.53 0.07
1.5 0.42 0.38 0.41 0.40 0.04
Table C.12: Relative invasion index of U251MG cells irradiated with carbon ion beams, pretreated
or not with 0.125 nM Epothilone B. The mean invasion index (S) and error bars are also reported.
C.3 Cell growth
In this section the results of each experiment on cell growth for U251MG cells irradiated
with carbon ion beams at different doses in combination or not with Epothilone B will
be presented.
In table C.13, the ratio between the number of cells counted at time t n(t) from irradia-
tion and that of cells initially seeded is reported as a function of time for each experiment.
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U251MG cells
t1 t2 t
n(t)
n0
1
n(t)
n0
2
n(t)
n0
error
Irradiation
Control sample
25 27 26.0 1.9 1.9 1.9 0.2
48.33 50.67 49.5 2.4 3.5 3.0 0.6
72.58 74.33 73.5 6.5 6.1 6.3 0.6
96.75 97 96.9 9.6 12.4 11.0 1.4
0.75 Gy
25 27 26.0 1.5 1.2 1.4 0.1
48.33 50.67 49.5 1.8 2.0 1.9 0.2
72.58 74.33 73.5 4.7 3.9 4.3 0.4
96.75 97 96.9 8.5 7.4 8.0 0.8
1.5 Gy
25 27 26.0 1.4 1.0 1.2 0.2
48.33 50.67 49.5 1.6 1.7 1.6 0.2
72.58 74.33 73.5 3.9 3.1 3.5 0.4
96.75 97 96.9 7.7 6.3 7.0 0.7
Irradiation + Epothilone B
0 Gy
24 27 25.5 1.1 1.4 1.3 0.1
47.67 49.67 48.7 1.9 1.9 1.9 0.2
72 73.17 72.66 4.2 3.3 3.8 0.4
96.17 96 96.1 5.7 6.8 6.2 0.6
0.75 Gy
24 27 25.5 0.9 1.0 1.0 0.1
47.67 49.67 48.7 1.4 1.5 1.5 0.1
72 73.33 72.66 3.9 2.6 3.3 0.6
96.17 96 96.1 5.4 5.1 5.2 0.5
1.5 Gy
24 27 25.5 0.8 0.9 0.8 0.1
47.67 49.67 48.7 1.3 1.2 1.2 0.1
72 73.33 72.66 2.3 2.5 2.4 0.2
96.17 96 96.1 2.9 4.5 3.7 0.8
Table C.13: Ratio between the number of cells counted at time t n(t) from irradiation and that
of cells initially seeded for U251MG cells irradiated with carbon ions combined or not with
Epothilone B (0.125 nM) at different doses, measured in two independent experiments. The mean
ratio and its error are also reported. t1 is the time from irradiation in experiment1, t2 is the same
for experiment2. t is the mean time.
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